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ABSTRACT
The aim of this project is to evaluate an alternative screening strategy using liquid-
based cytology (LBC), and supplementary detection of human papillomavirus (HPV) in 
cases of minor cytological abnormalities (atypical squamous cells of undetermined 
significance, ASCUS, and low-grade squamous intraepithelial lesion, LSIL). 
Within population-based screening in Stockholm, Sweden, we alternated screening 
using LBC with supplementary HPV testing in ASCUS and LSIL (LBC+HPV testing,
using Linear Array HPV genotyping Assay, Roche diagnostics) and conventional 
cytology (CC), from September 2005 to December 2006. LBC+ HPV testing (n=6075) 
and CC (n=4261) screening performance were compared. LBC+ HPV testing was 
evaluated over time (September 2005- December 2007).  Diagnostic performance of 
HR-HPV detection as a triage test to identify high-grade precancerous lesions (CIN2+) 
in cases of ASCUS and LSIL was assessed, and age-specific HPV prevalence was 
studied. To assess the cost-effectiveness of HPV triage compared with immediate 
colposcopy or repeated cytology as a follow-up strategy for ASCUS and LSIL, an 
economic analysis was carried out from the perspective of the Swedish healthcare 
system, based on data from previous studies. 
Comparing LBC+ HPV testing with CC, the adjusted OR for detecting CIN2+ and 
CIN3+ were 0.89 (95% CI: 0.64-1.25) and 1.02 (95% CI: 0.67-1.54) respectively. 
Detection of CIN2+ improved significantly over time for both methods. Positive 
predictive values were similar between methods for all endpoints. High-risk (HR-)
HPV was found in 71% of LSIL and 49% of ASCUS cases (p=0.001) with similar 
prevalence between groups in women >30 years. HR-HPV prevalence was age-
dependent in LSIL (p=0.01), with decreasing prevalence until age 50 years, followed 
by a slight increase. The negative predictive value of HR-HPV detection for 
histologically confirmed high-grade lesions was 100%. For women with ASCUS >30 
years, HPV triage is the least costly alternative, whereas immediate colposcopy with 
biopsy provides the most effective option at a modest additional cost.  
No obvious advantages of the LBC+ HPV testing strategy over CC were shown. 
However, detection of high-grade precancerous lesions improved significantly over 
time for both strategies. This finding suggests that introduction of LBC+ HPV testing 
may have lead to general improvement of expertise and increased vigilance in 
cytological interpretation. Observed changes underscore the importance of 
continuously monitoring rates of abnormal cytology to ensure balance and to guard 
against overdiagnosis or overconfidence in cytological evaluation. By using HPV 
reflex testing, additional extensive workup can safely be avoided in about 50% of all 
cases of ASCUS and LSIL among women ≥30 years. With highly sensitive HPV 
testing techniques at lower costs, HPV triage could become a cost-effective alternative. 
Cervical cancer screening will need to continuously adapt as HPV-vaccinated women 
reach screening ages and new potentially superior screening strategies are identified. 
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1 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Livmoderhalscancer är globalt sett den tredje vanligaste cancerformen bland kvinnor.
Varje år får mer än en halv miljon kvinnor diagnosen, och mer än en kvarts miljon 
kvinnor dör av sjukdomen. Symtom uppkommer vanligen sent i förloppet, då utsikterna 
för en effektiv behandling är dåliga. Cancerutvecklingen sker gradvis och förstadier till
sjukdomen (cervikal intraepitelial neoplasi, CIN) finns vanligen i många år innan 
förändringen blir elakartad.  
Välorganiserad screening med cellprov är ett effektivt sätt att förebygga utveckling 
av livmoderhalscancer, då avancerade CIN-förändringar, som kallas CIN2 och CIN3, 
kan upptäckas och behandlas. Med konventionell metodologi (CC=conventional 
cytology) tas cellprovet genom att celler som skrapats från livmodertappen stryks ut på 
glas, färgas och undersöks i mikroskop. Det finns två huvudsakliga former av 
cervixcancer: skivepitelcancer och körtelcellscancer. Insjuknandet i skivepitelcancer 
har minskat dramatiskt i Sverige sedan allmän screening med cellprov infördes. 
Screeningprogrammet tycks dock ha nått sin begränsning då ingen tydlig 
trendminskning av livmoderhalscancer setts de senaste 10 åren.  
Infektion med särskilda högrisk-typer av humant papillomvirus (HR-HPV) är 
nödvändig för utveckling av livmoderhalscancer. Sådana infektioner är vanliga, särskilt 
bland unga kvinnor, och läker vanligen ut spontant. Om infektionen blir kronisk kan 
den dock leda till cancerutveckling. 
Ett problem inom cellprovsbaserad screening är att merparten av alla avvikande 
prov består av lindriga cellförändringar. Lindriga cellförändringar kan indelas i två 
diagnosgrupper: ASCUS (atypiska skivepitelceller av oklar signifikans) och LSIL 
(lindrig intraepitielial skivepitelsförändring). Dessa förändringar är ospecifika, och 
CIN2 eller mer avancerade förändringar (CIN2+) finns bara i en minoritet av dessa fall. 
Det behövs bättre metoder för att identifiera de kvinnor som löper ökad risk för 
framtida livmoderhalscancer, så att överdiagnostik, överbehandling och onödigt 
psykiskt lidande kan minimeras. En möjlighet är att komplettera cellprovet med HPV-
test, så att kvinnor med ökad risk för framtida livmoderhalscancer kan särskiljas från 
dem med reaktiva förändringar, så kallad HPV-triage. HPV-test har en betydligt högre 
känslighet än cellprov för att upptäcka CIN2+, och därmed en god förmåga att förutse 
frånvaro av CIN2+. Det begränsas dock av sin dåliga förmåga att förutse sjukdom, 
framför allt bland unga personer där självläkande HPV-infektioner är vanliga. 
Ett enstaka cellprov innebär en begränsad möjlighet för att upptäcka CIN2+. 
Screeningens skyddseffekt är därför beroende av relativt tätt upprepade screeningprov. 
Cellprov är särskilt begränsat då det gäller att upptäcka förstadier till körtelscellscancer. 
Detta bidrar till att livmoderhalscancer ibland utvecklas även hos kvinnor som tidigare 
deltagit i screening och haft normala cellprov. En alternativ metod med vätskebaserat 
cellprov (liquid-based cytology=LBC) har utvecklats för att förbättra cellprovets 
kvalitet och underlätta bedömningen. Provtagningstekniken är densamma som vid CC, 
med skillnaden att cellerna slammas upp i fixerande vätska, och appliceringen på 
objektglas sker på cytologlaboratoriet. En fördel med LBC är att man enkelt kan göra 
kompletterande analyser, t.ex. HPV-test, utan att kvinnan behöver kallas för ett nytt 
prov, till skillnad från CC. Vissa studier visar att LBC har en bättre känslighet för att 
upptäcka förstadier till livmoderhalscancer.  
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Målet med det här projektet var att uvärdera en alternativ screeningstrategi med 
vätskebaserat cellprov och kompletterande HPV-test vid lindriga cellförändringar inom 
det svenska screeningprogrammet. 
Inom screeningprogrammet i Stockholm alternerades LBC med kompletterande 
HPV-test vid lätta cellförändringar (LBC+HPV-test) och CC från september 2005-
december 2006. Screening med LBC+ HPV-test och CC jämfördes avseende förmåga 
att upptäcka CIN, för olika grad av avvikelse indelat i grupperna CIN1+, CIN2+ och 
CIN3+. Metodernas positivt prediktiva värde, d.v.s. deras förmåga att förutse en 
onormal förändring, jämfördes. Screening med LBC+HPV-test utvärderades också över 
tid (september 2005-december 2007). HPV-testets diagnostiska förmåga att påvisa 
CIN2+ undersöktes. HPV-förekomsten i olika åldersgrupper vid ASCUS och LSIL 
studerades. För att undersöka kostnadseffektiviteten för HPV-triage vid uppföljning av 
ASCUS och LSIL gjordes en ekonomisk analys baserad på tidigare studier inom 
området.
Med LBC+HPV-test ökade andelen upptäckta CIN2+ med 45 % (från 1,1 till 1,6 %) 
under första året, och förmågan att förutse CIN2+ ökade markant. Andelen upptäckta 
förstadier till cancer ökade betydligt över tid, för båda metoderna. Skillnaden mellan 
metoderna var inte betydande (justerad oddskvot för CIN2+ 0,89 med 95 % 
konfidensintervall 0,64- 1,25; justerad oddskvot för CIN3+ 1,02 med 95 % 
konfidensintervall 0,67- 1,54). De positivt prediktiva värdena för CIN var likvärdiga för 
metoderna. Högrisk-HPV fanns i 71 % av alla LSIL- och i 49 % av alla ASCUS-fall. 
Bland kvinnor över 30 år var skillnaden i högrisk-HPV-förekomst inte betydande.
Ingen högrisk-HPV-negativ kvinna hade CIN2+ inom 2 år från cellprovet. Alltså var 
HPV-testets förmåga att förutse frånvaro av CIN2+ var utomordentligt god. För 
kvinnor över 30 år vars screeningprov visat ASCUS, var HPV-triage det billigaste 
uppföljningsalternativet, medan omedelbar undersökning av livmodertappen i 
mikroskop med riktade vävnadsprov var en mer effektiv metod för att detektera CIN2+, 
till en marginellt högre kostnad. 
Sammanfattningsvis påvisades inga uppenbara fördelar med att använda LBC+ 
HPV-test i screening jämfört med CC. Över tid fanns dock fanns en markant ökning av 
andelen upptäckta förstadier till livmoderhalscancer, för båda metoderna. Det är möjligt 
att införandet av den nya tekniken med LBC+ HPV-test ledde till en generell 
kompetenshöjning och en ökad vaksamhet vid bedömningen av cellprov. Med LBC är 
det nämligen lättare att se även subtila förändringar, som kan vara svåra att upptäcka 
med CC. De förändringar som observerades under studieperioden understryker vikten 
av att övervaka den totala andelen avvikande cellprovsfynd; detta för att balansera 
överdiagnostik mot övertro på den egna förmågan att visuellt kunna särskilja reaktiva 
förändringar från möjliga förstadier till cancer. Genom att använda kompletterande 
HPV-test kan ytterligare omfattande utredningar undvikas för ca 50 % av alla kvinnor 
vars screeningprov visat ASCUS och för dem över 30 år med LSIL. Om HPV-test med 
god diagnostisk förmåga används och kostnaderna för HPV-test reduceras kan 
kompletterande HPV-test bli en kostnadseffektiv strategi vid uppföljning av lindriga 
cellförändringar. Screeningprogrammet måste kontinuerligt anpassas allteftersom HPV-
vaccinerade kvinnor når åldrar som omfattas av screening och nya lovande 
screeningmetoder blir tillgängliga. 
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2 BACKGROUND 
2.1 The uterine cervix 
The uterine cervix is the lower third of the uterus and is composed of dense
fibromuscular tissue, is about 3 cm long and has a diameter of about 2.5 cm. The outer 
part of the cervix (ectocervix) protrudes into the vagina, whereas the upper two-thirds 
(endocervix) of the cervix lies above the vagina (Figure 2.1). 
Figure 2.1. Front and side-view of female internal organs. From Comprehensive Cervical Cancer 
Control: a guide to essential practice. Integrating Health Care for Sexual and Reproductive Health 
and Chronic Diseases, World Health Organization, Figure 2.2, page 29, (2006).
http://screening.iarc.fr/planningguides.php (latest accessed on 16th of March 2011). Reproduced with 
kind permission from the World Health Organization.
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The cervical canal runs through the cervix. The endocervical canal is lined by thin 
glandular epithelium which meets the stratified squamous epithelium of the 
ectocervical surface. The opening of the canal into the uterus is called the internal os, 
and the opening towards the vagina the external os. The transition between the 
monolayer of glandular epithelium (also called columnar) and the stratified squamous 
epithelium creates the original squamocolumnar junction (SCJ) (Figure 2.2). Its 
location in relation to the external os depends on the age and hormonal status of the 
woman; in young women it can be visualized at the ectocervical surface, whereas in 
older women it is often located within the endocervical canal. 
When the thin glandular epithelium is exposed to the acidic environment of the vagina, 
the columnar epithelium is gradually replaced by metaplastic squamous epithelium 
(which derive from glandular reserve cells) before it meets the true stratified squamous 
epithelium and gives rise to the new SCJ. The transformation zone (TZ) is the area 
between the original and the new SCJ. The TZ is a crucial area in the pathogenesis of 
cervical cancer (2006 ; Richart, 1969; Sellors J.W., 2003).
Figure 2.2. A schematic diagram of the transformation zone. From Sellors J.W. and Sankaranarayanan 
R. Colposcopy and Treatment of Cervical Intraepithelial Neoplasia. A Beginner's manual. Lyon, 
France, IARCPress, 2003. http://screening.iarc.fr/doc/Colposcopymanual.pdf (latest accessed on 16th 
of March 2011). Reproduced with kind permission from the International Agency for Research on 
Cancer, WHO. 
2.2 Cervical cancer     
2.2.1 Epidemiology 
Cervical cancer is a preventable disease. In spite of this fact it is one of the leading 
cancers among women worldwide. In 2008 it was the third most common cancer in 
women after breast and colorectal cancer, with an estimated 529 000 new cases and 
275 000 deaths from cervical cancer, of which 88% were in developing countries. In 
some regions it is the number one cause of cancer-related deaths (Ferlay et al). Like 
other cancers which are mainly caused by infectious agents, such as liver cancer and 
stomach cancer, the disease is markedly overrepresented in less developed countries 
(Jemal et al). More than 85% of the global burden of cervical cancer occurs in 
developing countries. The primary high-risk areas are Eastern and Western Africa with 
cumulative incidence risk (0-74 years) of 3.8%, Southern Africa (2.9%), South Central 
Asia (2.6%), Middle Africa and South America (2.5%).  
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Figure 2.3. (a) Estimated cumulative incidence risk (0-74 years): cervix uteri cancer. (b) Estimated age-
standardized incidence and mortality rates for cervix uteri cancer. From “Estimates of worldwide 
burden of cancer in 2008: GLOBOCAN 2008”, by Ferlay J, Shin HR, Bray F, Forman D, Mathers C, 
Parkin DM, Int J Cancer, 127, 2008 (Figure 12 a and b, page 2913), 2010 UICC,. This material is 
reproduced with kind permission of John Wiley & Sons, Inc. 
 Areas where the cumulative incidence risk of cervical cancer is very low (0.5%) 
include Western Asia, Northern America and Australia (Figure 2.3) (Ferlay et al).
The huge variation in incidence between regions reflects differences in availability of 
preventive programs against cervical cancer, lifestyle and the position of women in 
society, whereas the variation of the mortality: incidence ratio (also called fatality) 
reflects the inequalities in accessibility of well-functioning health services delivery to 
assure detection and appropriate treatment of cervical precancer and cancer (Jemal et 
al; Sankaranarayanan & Ferlay, 2006). Before onset of screening in developed 
countries, incidence of cervical cancer  was similar to that of developing countries 
(Gustafsson et al, 1997).
In Sweden, population-based cervical cytology screening has been offered since the late 
1960’s, the major reason that cervical cancer is a rare disease today (Andrae et al, 2008; 
Bergstrom et al, 1999; Gunnell et al, 2007). Cancers of the breast, lung, colorectum, 
uterine body, and ovaries are all more common among Swedish women. In 2009, 437 
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new cases were diagnosed, representing 1.7% of all cancers among women. Of these 
women, 44% were 20-49 years old (Socialstyrelsen, 2010). Cervical cancer is indeed a 
disease of young women. In more developed countries the age standardized incidence 
rates (ASR) generally begin to increase earlier (probably due to earlier detection) and 
increase until 40 years of age after which a plateau is reached, whereas in less 
developed regions ASR continues rising to a much higher incidence level until an age 
of about 60 years (Kamangar et al, 2006).
2.2.2 Clinical manifestations  
Development of cervical cancer is a multistep process, which is almost always induced 
by a persistent oncogenic human papillomavirus infection (high-risk (HR)  HPV) that 
disrupts control over cell growth and which, over years or even decades, leads to 
asymptomatic precancerous lesions that can progress into invasive cancer (zur Hausen, 
2009). Pathophysiology will be described in greater detail in Chapter 2.3. Small 
invasive cancers that are not clinically detectable, also called microinvasive cancers, are 
also usually asymptomatic. These cancers can only be detected through a screening test 
for abnormality. However, most cancers are not discovered until they become 
symptomatic, which often occurs at a relatively advanced stage, especially if the 
woman is not sexually active. For early detection of cervical cancer, women who 
present with one or more of the following complaints should be evaluated for possible 
cervical cancer: irregular bleeding, postcoital bleeding and persistent vaginal discharge 
(especially if persistent after treatment for bacterial sexually transmitted infection) 
(2006 ). Early and late symptoms and signs of cervical cancer are listed in Table 2.1.
Table 2.1. Symptoms of invasive cervical cancer. From Comprehensive Cervical Cancer Control: a 
guide to essential practice. Integrating Health Care for Sexual and Reproductive Health and Chronic 
Diseases, World Health Organization, Table 6.1, page 169, 2006.
http://screening.iarc.fr/planningguides.php (latest accessed on 16 of March 2011).  Reproduced with 
kind permission from the World Health Organization. 
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2.2.3 Prognosis and treatment 
The clinical suspicion of cervical cancer requires examination including a biopsy or 
diagnostic conization for a definitive histological diagnosis. The main forms of cervical 
cancer are squamous cell carcinoma (SCC), adenocarcinoma (ADC) and a mixed form 
called adenosquamous carcinoma. Cancers of non-epithelial origin also occasionally 
occur in the uterine cervix. Once the diagnosis is confirmed, the stage of the disease 
needs to be determined to formulate a suitable treatment (2006 ).
A widely used and recommended system has been elaborated by the International 
Federation of Gynecology and Obstetrics (FIGO), and is described in Table 2.2 (2006 ; 
Pecorelli et al, 2009; Quinn et al, 2006). It is based on the spread of the disease in the 
pelvis and to distant organs. The extent of growth of the cancer is assessed clinically 
including a speculum examination of the vagina and a rectal examination, often made 
under general anesthesia. Microinvasive carcinomas are an exception since these cases 
are not clinically detectable and instead staged according to pathological criteria of the 
depth and width of the invasive lesion. Intravenous pyelogram or an abdominal 
ultrasound can be performed to detect occlusion of the ureters. Additional examinations 
can be helpful for staging, such as cystoscopy, proctoscopy, an endocervical curettage 
or smear, a chest X-ray or a skeletal X-ray or bone scan. Magnetic resonance imaging 
or a computerized tomography scan of the pelvis and abdomen is encouraged for more 
objective determination of tumor size in (Pecorelli et al, 2009). One should also 
consider associated diseases, such as anemia, HIV/AIDS and syphilis.  
Tumor stage is the most reliable predictor of clinical outcome for patients with invasive 
cervical cancer. In developing countries only 5% of cervical cancers are found at an 
early stage (including FIGO stages IA1-IIA) (2006 ). The results of a nationwide audit 
of the Swedish screening program (Andrae et al, 2008), including all cases of invasive 
cervical cancers reported to the high-quality Swedish Cancer Registry from 1999 until 
the end of 2001 found that among these women (n=1230), 305 (25%) cases were 
assumed to be screen-detected whereas 925 (75%) cases were assumed to be 
symptomatic. Among screen-detected cancers, only 9% were advanced-stage cancers 
(FIGO stage II or higher), whereas among symptomatic women 48% were advanced 
cancers. 
Lymphovascular space invasion, tumor spread to regional lymph nodes, and large 
tumor size worsen the prognosis across all FIGO stages, especially in earlier stages 
(Pecorelli et al, 2009; Quinn et al, 2006). Non-SCC generally have worse prognosis 
than ADC across all FIGO stages. Age ≥50 years is a predictor of poor prognosis only 
in women with FIGO stage I cancer (Quinn et al, 2006).
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Table 2.2. Summary of the FIGO stages with prognosis figures for cases managed with optimal treatment 
(adapted from Comprehensive Cervical Cancer Control: a guide to essential practice. Integrating 
Health Care for Sexual and Reproductive Health and Chronic Diseases, World Health Organization 
(2006), page 172-176. http://screening.iarc.fr/planningguides.php (latest accessed on 16 of March 
2011) ▪ Subdivision of Stage IIA according to Pecorelli et al, 2009.
In cases of tumors >2 cm, protocols with neoadjuvant chemotherapy to shrink tumors 
before fertility-sparing surgery, have been used. For tumors >2cm, fertility-sparing 
surgery is still considered an experimental procedure and needs further evaluation (Rob
et al). If preserved fertility is not a high priority, simple hysterectomy (surgical removal 
of the uterus including the cervix) with or without lymphadenectomy is indicated for 
FIGO 
stage 
Extension of tumor 5-year survival 
Stage I Carcinoma confined to the cervix. 
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microscopy. 
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horizontal spread 
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Stage 
III 
Tumor has spread.  
IVA Spread to involve the mucosa of the bladder or rectum. ~10% 
IVB Spread to distant organs, such as extrapelvic lymph nodes, 
kidneys, skeleton, lungs, liver and brain. 
<5% 
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FIGO stage 1A1 and sometimes IA2 cancers. For cancers of FIGO stage up to IIA1, 
standard treatment includes vaginal or abdominal radical hysterectomy (surgical 
removal of the uterus, parametria, and upper 2 cm of the vagina) and lymphadenectomy 
(2006 ; Herzog, 2003). For more advanced cancers, treatment including radical 
radiotherapy or a combination of chemotherapy and radiotherapy is preferred. 
Radiotherapy and chemotherapy can also be used to supplement surgery (2006 ).
2.3 Pathogenesis 
2.3.1 The causative role of human papillomavirus infection 
The Italian surgeon and researcher Rigoni-Stern, born in 1810 in Verona, Italy, 
systematically recorded data on cancer incidence and mortality. He found that uterine 
cancer (without distinction between the uterine cervix and body) was common among 
married women, widows and prostitutes but uncommon among nuns and virgins, and 
suggested that the disease was related to sexual activity (Rigoni-Stern, 1842).
More than 100 years later, an association between human papillomavirus (HPV) 
infection and cervical cancer was first suspected, from anecdotal reports of conversion 
of condyloma accuminata into SCC (zur Hausen, 1977). The hypothesis was 
strengthened by the failure to detect the long suspected etiologic agent herpes simplex 
virus, in cervical cancer biopsies (zur Hausen et al, 1974b). Pioneering experimental 
work was made by Harald Zur Hausen and co-workers in the 1970’s and onwards. In 
2008 he was awarded the Nobel Prize in Physiology or Medicine for his work.  
An early experiment aimed to examine the relation of human wart virus with a number 
of benign and malignant human tumors (zur Hausen et al, 1974a). Viral DNA from 
plantar warts was isolated. With the aid of Escherichia coli RNA polymerase, 
radioactive complementary RNA (cRNA) was produced and used as a probe for 
detection of viral DNA. High viral DNA concentrations were found in plantar warts, 
and found to a lower extent in verrucae vulgares, whereas laryngeal papillomas, 
condyloma accuminata and cervical cancer, with the exception of one case with cRNA 
binding slightly above background values, were negative. The hypothesis of the 
possible existence of different types and subtypes of HPV was presented, and 
additional studies were launched to identify and characterize novel HPV types in 
human tumors.
Presence of HPV DNA in cervical cancer biopsies was first demonstrated in 1982 
(Green et al, 1982). The year after, HPV 11 DNA was found in two cases of cervical 
carcinoma in situ and in one case of invasive cervical cancer out of totally 24 biopsies 
from in situ or invasive genital carcinomas (Gissmann et al, 1983). By using HPV 11 as 
a probe, a novel HPV type could be isolated from a cervical cancer biopsy (Durst et al,
1983). This HPV type was designated as HPV 16, and was found in 61% (11/18) of all 
cervical cancer biopsies from German patients and 35% (8/23) of such samples from 
Kenya and Brazil. HPV 16 was frequently detected in cervical intraepithelial neoplasia 
(CIN) , but was uncommon in cases of common genital warts (Crum et al, 1984). This 
breakthrough was followed by the isolation of the second main oncogenic HPV type, 
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HPV 18, which was detected in cervical cancer biopsies and several cervical cancer 
derived cell lines, but not in benign tumors (reviewed in (zur Hausen, 2009)).
In the 1980s and 1990s central carcinogenic properties of specific HPV types were 
uncovered, and will be presented in greater detail in paragraph 2.3.5.
Global epidemiological studies identified HPV 16, 18, and a few other HPV types as 
key etiologic factors in cervical cancer (Munoz et el 1992, Bosch et al. 1992 (Bosch et 
al, 1995). With newer sophisticated techniques for HPV detection, i.e. polymerase 
chain reaction (PCR) and histopathological re-evaluation of both HPV-positive samples 
and the small portion of initially HPV-negative samples, HPV could eventually be 
identified in virtually all (99.7%) adequate cervical cancer samples (Walboomers et al,
1999).  
2.3.2 Classification of papillomaviruses 
In 2010, 189 different papillomavirus (PV) types had been identified (Bernard et al). 
This figure has rapidly increased since 2004, when the number was 118 (de Villiers et 
al, 2004).  PVs are small (~8kb), non-enveloped DNA viruses that infect epithelium of 
vertebrates. The PV types known today have been isolated from humans (120 types), 
non-human mammals, birds, and reptiles.  
Classification of the different PVs in the Papillomaviridae family is based on 
nucleotide sequence similarities with certain medical and biological properties (de 
Villiers et al, 2004). The L1 gene encodes for the major viral capsid protein L1, which 
together with the L2 protein, comprises the complete capsid. The viral structure is 
described in greater detail in section 3.3.4. L1 is overall the most conserved open 
reading frame (ORF) of the PV genome. Comparisons of whole genome sequences lead 
to a similar distribution of inter-related HPV types, as found when comparing L1 ORFs 
(de Villiers et al, 2004). Classification of PVs follows the guidelines below: 
- Genera: higher-order clusters of PV types, e.g. genital HPVs. Different genera 
have less than 60% nucleotide sequence homology in the L1 ORF. Within a 
genus, full-length sequences of whole genomes have more than 23%, but less 
than 43% nucleotide homology. 
- Species: lower order clusters of PV. Species within a genus share 60-70% 
nucleotide identity, and have identical or similar biological properties. 
- Type: a novel isolated PV type is recognized as such if the L1 ORF nucleotide 
sequence differs by more than 10% compared with the most similar previously 
known PV type. The traditional PV types within a species share 71-89% 
nucleotide identity within the complete L1 ORF. 
- Subtype: If the difference in L1ORF nucleotide sequence is 2-10% compared 
with the most similar previously known PV type, it is considered a new 
subtype, and a variant if the difference is <2%. 
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The main PVs infecting the anogenital tract of humans belong to the Alpha genus, 
which includes ~70 different HPV types (Bernard et al).
A recent large meta-analysis including 30 848 cases showed that the most frequently 
occurring HPV types in invasive cervical cancers are HPV 16, 18, 58, 33, 45, 31, 52, 
35, 59, 39, 51, and 56, in decreasing order of frequency. HPV 16 and/or 18 were 
associated with 73% of all cervical cancer cases (Li et al). This is in accordance with 
the HPV types defined as carcinogenic by the IARC(Bouvard et al, 2009). Of these, the
eight HPV types that are most frequent in cervical cancer accounted for 91% of 8977 
HPV-positive cervical cancers of epithelial origin in a worldwide retrospective cross-
sectional study on HPV genotype distribution (de Sanjose et al). Four carcinogenic 
HPV types are less frequently found in cervical cancer (HPV 39, 51, 56, and 59), but 
evidence is considered sufficient to define them as carcinogenic (Bouvard et al, 2009). 
The carcinogenic HPV types belong to species 5 (HPV 51), 6 (HPV 56), 7 (HPV 18, 
39, 45, and 59), and 9 (HPV 16, 31, 33, 35, 52, and 58).
HPV 68 was classified as “probably carcinogenic to humans.” Other HPV types were 
classified as “possibly carcinogenic” due to limited evidence of carcinogenicity or their 
close phylogenetic relationship with carcinogenic types (Bouvard et al, 2009). Low-risk 
risk HPVs cause benign and low-grade mucosal lesions (de Villiers et al, 2004).
2.3.3  Genital HPV infection prevalence 
Infection with HPV is the most common sexually transmitted infection. About 50-80% 
of sexually active men and women are estimated to become infected with low- or high-
risk HPV sometime in their lives (reviewed in (Stanley)). From a 2007 meta-analysis 
based on reports of HPV prevalence from 1995 to 2005 (de Sanjose et al, 2007), an 
estimate was made of the worldwide age-specific HPV infection spectrum among 
women with normal cytology. The overall adjusted prevalence was 10.4%, with a large 
variation between geographic areas; the lowest observed prevalence was in 
Southeastern Asia (6.2%) and the highest in Eastern Africa (31.6%). Adjusted 
prevalence in Northern Europe was 7.9% including studies from Sweden, Denmark, 
and the UK, a figure close to the 6.8% (n=6123) HR-HPV-positive women aged 32-38 
years in a population-based screening in Sweden (Forslund et al, 2002) and to a similar 
cohort, where 7.1% to 11.0% were HR-HPV positive (n=12527), depending on the 
HPV detection assay used (Wahlstrom et al, 2007).
The overall genital HPV prevalence in men is lower than in women, suggesting that 
penile tissues may be more resistant to HPV infections (Partridge & Koutsky, 2006).
HPV 16 was the most prevalent HPV type in all regions except Eastern Africa, Japan, 
and Taiwan, where it was the second most prevalent type after HPV 52 (de Sanjose et 
al, 2007). Prevalence was high among young women (>20%) irrespective of the level 
of development of each country, except in Asia where figures were lower. After the age 
of 25 years, HPV prevalence was higher in less developed countries than in more 
developed countries (Figure 2.4). The most significant reduction of HPV prevalence 
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was seen after age 35 years, using broad age groups as shown in Figure 2.4. After age 
45 years, HPV frequency increased except in Asia, where the decline continued with 
increasing age.  
Figure 2.4. Worldwide estimates of age-specific HPV prevalence by country-specific development status 
in women with normal cytology. Reprinted from, The Lancet Infectious Diseases, 7, de Sanjose S, Diaz 
M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX, Worldwide prevalence and genotype 
distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis,
453-9, 2007, with permission from Elsevier. 
2.3.4 HPV transmission and viral life cycle 
Sexual intercourse is the main route of transmission of genital HPV infection, although 
skin-skin and skin-mucosa transmission also occur (Burchell et al, 2006; Winer et al).
Most HPV infections are cleared by the immune system without causing any 
symptoms. However, a small fraction of all these infections persist, and may over time 
cause genetic damage that leads to loss of control of the cell cycle and accumulation of 
harmful mutations, which eventually lead to formation of precancerous lesions and 
progression to invasive cancer (zur Hausen, 2002).
The TZ (Figure 2.2) is, as mentioned, an important site for HPV infection, and cervical 
cancers are considered to arise mainly in this region. The site is a fragile spot where the 
virus can penetrate the epithelial lining through microscopic wounds to reach the basal 
layer cells (2006 ; Horvath et al; Richart & Barron, 1969; Sellors J.W., 2003). The 
virion probably enters the basal epithelial cell by primary binding of the major viral 
capsid protein L1 to the basement membrane, followed by infectious transfer and 
binding to heparan sulphate proteoglycans present on the cell surface of keratinocytes 
(and many other cell types). This binding causes conformational change of the viral 
capsid that enables cleavage of the minor capsid protein L2 and viral binding to a more
specific co-receptor, mediating internalization of the virus (reviewed by (Horvath et 
al)). A more detailed description of viral genetics is presented in paragraph 2.3.5. 
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In the basal layer of the epithelium, viral gene expression is low, with only modest 
expression of genes that promote proliferation and lateral expansion of the cells (Figure 
2.5). The virus uses the differentiation program of the epithelium for its replication, and 
in early infection, whole infectious viral particles are shed with the desquamating 
superficial epithelial cells (reviewed in (zur Hausen, 1996; zur Hausen, 2002).
Figure 2.5. The human papillomavirus life cycle.  Reprinted by permission from Macmillan Publishers 
Ltd: Nature Reviews Cancer (Zur Hausen H, Papillomaviruses and cancer: from basic studies to 
clinical application, pages 342-50), 2002. 
Incubation time (infection without viral replication or carcinogenic effects) varies from 
3-4 weeks to years of latency. The virus evades detection and elimination through 
several mechanisms. Important factors include absence of viremia, low levels of viral 
protein expression, and absence of cytolysis. The virus replicates and assembles in cells 
that are already destined to die and desquamate, consequently producing no “danger 
signal” to the immune system. Moreover, the interferon response, which is key to 
antiviral protection, is suppressed by the E6 and E7 proteins of HR-HPV (see below). 
The E7 protein downregulates the Toll-like receptor 9, contributing to evasion of innate 
immunity, which delays activation of adaptive immunity. However, eventually most 
HPV infections are cleared within 18 months. Only about 10-20% of infections persist 
and may lead to development of cervical precancerous lesions that can progress to 
invasive cancer (reviewed in (Stanley)). 
  
2.3.5 Mechanisms of HPV-induced carcinogenesis 
The ~8kb genome is an episome, i.e. a circular double-stranded DNA molecule (Figure 
2.6). It carries an upstream regulatory region (URR) and eight ORFs of six early genes 
(E1, E2, E4, E5, E6, and E7) and two late genes (L1 and L2), named according to 
“early” or “late” expression in the viral life cycle. Although LR- and HR-HPV types 
have a similar genetic structure, their biological functions are different. The 
mechanisms listed below are described for HR-HPV, and are often absent or weak for 
LR-HPV types (Pim & Banks). The oncogenic potential also varies between individual 
HPV types, as reflected by the different extent to which they induce cancer.  
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In early productive infection and CIN1, only weak transcription of viral early genes is 
seen in the epithelial basal layer (Figure 2.5), and expression increases in the more 
differentiated cells of the superficial layers. Onset of expression of late genes takes 
place in the differentiated cells of the most superficial layers. In high-grade CIN and 
invasive cervical carcinoma (ICC), stronger expression of viral early genes is seen in 
the basal layers, and distribution is more eventhroughout the epithelium, whereas the 
expression of late genes is low or absent and viral replication is low (Durst et al, 1992).
Figure 2.6. The organization of episomal (circular) HPV DNA and its integration into host DNA. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer (Zur Hausen H, 
Papillomaviruses and cancer: from basic studies to clinical application, pages 342-50), 2002. 
The E1, E2, and E4 proteins are often referred to as regulatory proteins. E1 is a helicase 
and is recruited to the viral origin of replication in the URR by E2 where it forms DNA 
replication machinery together with cellular proteins (Yugawa & Kiyono, 2009).
During S-phase in the basal epithelial cells, the episomal DNA replicates together with 
cellular DNA, and the viral episomes become equally distributed in daughter cells after 
cell division. E2 seems to have a crucial role for correct segregation, anchoring the viral 
episomes to the mitotic chromosomes (Johansson et al, 2009). E2 also regulates early 
viral gene expression, and is important for genome amplification. The increased levels 
of E2 needed for viral replication may eventually lead to the repressive downregulation 
of E6/E7, resulting in loss of the environment needed for viral DNA synthesis. This has 
been interpreted as a timing mechanism for viral replication. The assembly of viral 
particles in the superficial epithelial layers is thought to require E2 in addition to L1 
and L2. The structural proteins L1 and L2 comprise the viral capsid, and are usually not 
expressed in advanced precancerous lesions and cancer.  
Less is known about the E4 protein. It accumulates in the cell at the time of viral 
genome amplification. Loss of E4 has been observed to disrupt late events in viral 
replication. It has also been observed that E4 can relocate cyclin/cyclin dependent 
kinase complexes from the nucleus to the cytoplasm, thereby preventing progression 
through mitosis (reviewed in (Doorbar, 2006)). It has also been suggested that E4 
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influences E2 function, varying the amount of E2 available in the cell (Davy et al,
2009).
The genes E5, E6, and E7 possess proliferation-stimulating properties. The E5 protein 
is most important in early stages of infection. It is a transmembrane protein present 
mainly in the endoplasmic reticulum. It is thought to increase recycling of growth 
factor receptors on the cell surface, thereby increasing epidermal growth factor-
mediated signaling, leading to maintenance of a replication-competent environment in 
the upper epithelial layer (Doorbar, 2006). In addition to epidermal growth factor 
receptor, E5 interacts with the platelet-derived growth factor-beta and the colony-
stimulating factor 1 receptor (Hwang et al, 1995). Moreover, E5 seems to be an 
important factor in immune evasion: it reduces HLA class-I molecules present on the 
cell surface, thereby leading to reduced recognition of infected cells by cytotoxic T-
lymphocytes (Campo et al).
HR-HPV E6 and E7 are considered the main viral oncogenes, with the tumor 
suppressor proteins p53 and pRb as their main targets (Figure 6). The functions of E6 
and E7 differ between HPV types. Carcinogenicity in humans has only been proved for 
the twelve HPV types designated as HR-HPV (Bouvard et al, 2009). 
The transcription of E6 and E7 in cervical cancer was first described in 1985 (Schwarz
et al, 1985). They are consistently expressed in cervical cancer, and inhibiting their 
expression blocks the malignant phenotype of the cells (Munger et al, 1989). The 
binding capability of the E7 protein to tumor suppressor protein pRb (Dyson et al,
1989) and that of the E6 protein to tumor suppressor protein p53 (Werness et al, 1990) 
were discovered only a few years later. Acting one by one, E6 and E7 are able to 
induce keratinocyte immortalization and transformation, but acting together they 
potentiate the transforming effect (Munger et al, 1989). Both E6 and E7 contribute to 
evasion of immune response (McLaughlin-Drubin & Munger, 2009).  
As a regulator of the cell cycle checkpoints G1/S and G2/M, p53 is a key player in 
tumor suppression, also called “the guardian of the genome.” DNA damage leads to 
activation of p53 that induces high expression of p21, resulting in cell cycle arrest and
apoptosis. E6 counteracts these functions of p53 through complex formation with p53 
with subsequent ubiquitin-mediated degradation. Lack of p53 function leads to 
accumulation of mutations and aneuploidy, leading to cell transformation (Longworth 
& Laimins, 2004). It has also been suggested that loss of p53 leads to inhibition of 
differentiation through reduced activation of Notch-1, a determinant of keratinocyte 
differentiation (reviewed in (Yugawa & Kiyono, 2009)). E6 can also indirectly 
downregulate p53 activity, through association with its co-activator p300/CBP. 
Moreover E6 blocks apoptosis through p53-independent pathways, e.g. by blocking the 
mitochondrial proapoptotic Bak, which results in apoptosis resistance and an increase 
in chromosomal instability (zur Hausen, 2002). E6 probably also interacts with the 
PDZ protein family, involved in maintenance of cell polarity, formation of cell-cell 
adherence junctions, and cellular signaling. The binding of E6 with such proteins lead 
to degradation of the PDZ protein, which is suggested to contribute to transformation 
and immortalization. Moreover the E6 protein has the ability to activate telomerase, an 
enzyme that prolongs the telomeres at chromosome ends. Telomeres normally shorten 
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with each cell division, eventually leading to senescence. Telomerase activity is 
normally absent in somatic cells. E6 also activates telomerase indirectly by acting on 
other factors, as through ubiquitin-mediated degradation of NFX1-91, a telomerase 
repressor, following which telomerase can be activated through complex formation 
involving E6 and c-myc and other factors ((Longworth & Laimins, 2004; Yugawa & 
Kiyono, 2009).
The ability of the E7 protein to associate with the pRb protein family is central to its 
immortalizing and transforming capability. pRb proteins are negative regulators of cell 
cycle progression from G1 to S-phase. The unphosphorylated form of pRb represses 
initiation of S-phase through complex formation with the E2F/DP1 transcription factors 
which stimulate expression of gene products involved in transition into S-phase. 
Normally, pRb is phosphorylated by cyclin-kinase complexes during progression from 
G1 to S-phase, leading to release of E2F, which stimulates transcription of genes 
involved in DNA synthesis. Binding of E7 to pRb leads to release of the same 
transcription factors and constitutive activation of the same genes. E7 can also cause 
degradation of pRb through ubiquitin-mediated degradation and might enhance 
phosphorylation of pRb through interaction with cyclins and cyclin-dependent kinases 
(CDKs).  This effect can be enhanced by blocking the activities of the CDK inhibitors 
p21 and p 27, leading to an uncontrolled cell cycle (Longworth & Laimins, 2004; 
Yugawa & Kiyono, 2009). Moreover, E7 induces abnormal centrosome numbers, 
leading to disorganized segregation of chromosomes during cell division, contributing 
to genomic instability (McLaughlin-Drubin & Munger, 2009).
In the course of carcinogenesis, viral DNA becomes integrated into the host cell 
genome, a process that disrupts the E2 gene (Schwarz et al, 1985). Due to their 
location, the E4, E5, and part of L2 are sometimes partially deleted after integration. 
Emergence of cells with high-level expression of E6 and E7 through integration of viral 
DNA and loss of E2 is considered to be a rate-limiting step for cervical carcinogenesis 
(Yugawa & Kiyono, 2009). In the carcinogenic process, integration occurs randomly 
over the whole genome with predilection for genomically fragile sites, and may cause 
deregulation of cellular genes (Wentzensen et al, 2004). Deregulated E6 and E7 
expression can lead to increasing genomic instability with increased risk of 
accumulating genetic and epigenetic changes. As a result of activation of oncogenes 
and/or inhibition of tumor suppressor genes, cellular clones with a growth advantage 
may arise and undergo malignant progression (Yugawa & Kiyono, 2009).
2.3.6 Precancerous lesions of the cervix 
Cervical carcinogenesis is a stepwise process, and 15-30 years are usually required for 
the increasingly abnormal (dysplastic) cervical epithelial lesion to progress into 
invasive cancer. The cervical intraepithelial neoplasia (CIN) terminology is based on 
the histological appearance and biological behavior of cervical lesions (Figure 2.7), in 
which CIN1 denotes mild dysplasia in which abnormal cells are seen in up to one third 
of the epithelium, CIN2 moderate dysplasia with abnormal cells in up to two thirds of 
the epithelium, and CIN3 corresponding to carcinoma in situ with abnormal cells in the 
full thickness of the epithelium (Richart, 1969). When cells of the lesion break through 
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the epithelial basement membrane it is by definition invasive. Since the glandular 
epithelium of the cervix is a monolayer, there is no such stepwise division of potentially 
precancerous lesions; precancerous lesions that arise from these cells are called 
adenocarcinoma in situ (AIS) or glandular intraepithelial neoplasia (GIN). 
Figure 2.7. Progress from normal epithelium to invasive cancer. From Comprehensive Cervical Cancer 
Control: a guide to essential practice. Integrating Health Care for Sexual and Reproductive Health 
and Chronic Diseases, World Health Organization, Figure 2.8, page 38 (2006),
http://screening.iarc.fr/planningguides.php (latest accessed on 16 of March 2011). Reproduced with 
kind permission from World Health Organization. 
The risk of progression to cervical cancer increases with the grade of dysplasia. Several 
attempts have been made to clarify the prognosis related to the different grades of CIN, 
with attendant difficulties presenting reliable data since management of such lesions 
usually involves at least taking a biopsy, thereby interfering with the natural course of 
the disease. Moreover, it is ethically unacceptable to passively await possible 
occurrence of invasive cancer in cases where CIN is suspected.  
One review was based on studies including prospective follow-up of women abnormal 
cytology, with results based on cytology, histology, and/or colposcopy (Ostor, 1993).  
Follow-up time was highly variable between studies, and most studies ended with 
detection of CIN3. For CIN1, the rate of regression was 60%, persistence 32%, 
progression to CIN3 was 10%, and progression to invasion 1%. For CIN2, the 
corresponding figures were 43%, 35%, 22%, and 5%, and for CIN3 rates were 33% 
regression, 56% persistence, and >12% progression to invasion. The latter figure is 
probably an underestimate due to design of the included studies, and because detection 
of CIN3 calls for action.
A large cohort study was undertaken of Canadian women screened 1962-1980, during 
which time management was usually conservative if cervical cytology showed mild 
and moderate dysplasia. Results showed a high rate (88%) of regression to normal in 
cases of mild dysplasia, and a 10% risk of progression to severe dysplasia or worse, 
within a 10 year follow-up period (Holowaty et al, 1999). For screening cytology 
showing moderate dysplasia, regression to normal occurred in 54% of cases and 
progression to CIN3 or worse in 32%, within the same follow-up period.
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Lessons were learned from an unethical study conducted in New Zealand 1965-1974 
(McCredie et al, 2008), aimed at proving the theory of CIN3 as a precursor to cervical 
cancer to be wrong. Treatment with curative intent was withheld from women with 
histologically confirmed CIN3. Medical records were reviewed in 2001-2002 for the 
1229 women included in the study following the judicial inquiry. In 143 women 
managed with punch or wedge biopsy alone, the cumulative incidence of invasive 
cancer of the cervix or the vaginal vault was 31% (95% CI: 23-42%), and 50% (95% 
CI: 37-65%) in the subset of 92 women who had persistent CIN3 for 24 months.   
A diagnosis of CIN2 or more advanced lesions is often referred to as a “high-grade 
cervical lesion” or CIN2+. Grouping these diagnoses together may be questionable. A 
Costa Rican population-based study of CIN and HPV infection including pathologic 
review showed that CIN3 was confirmed in 81% of patients compared with 61% for 
CIN2. CIN3 was associated with HR-HPV positivity in 93% of cases, compared with 
72% for a CIN2 diagnosis (Carreon et al, 2007).
2.3.7 Risk factors 
Only a small fraction of all HR-HPV infections will lead to development of cancer, 
implying that additional risk factors contribute to carcinogenesis. Risk factors are often 
related to HPV infection, e.g. through increased exposure to the infection, biological 
factors facilitating transmission, persistent HPV infection, cell immortalization, 
transformation, tumor progression, or host susceptibility to the carcinogenic effects of 
HPV. 
Lack of availability of effective cervical screening and treatment for precancerous 
lesions is a crucial risk factor for developing cervical cancer and dying from the disease 
due to late diagnosis, as is underscored in paragraph 2.2.1 by the extreme variations in 
ICC incidence and mortality. In countries where well-organized population-based 
cervical screening programs exist, unscreened or underscreened women are a high-risk 
group and will be discussed in paragraph 2.4.3. 
Immunosuppression due to HIV infection or immunosuppressive treatment after organ 
transplantation increases the risk of malignancies, especially for cancers with a known 
infectious etiology, including all HPV-related cancers: cervical, vulvovaginal, penile, 
anal, and oropharyngeal cancer (Grulich et al, 2007). HIV-positive women exhibit 
higher rates of HPV infection with multiple oncogenic types, higher prevalence of CIN, 
and are at increased risk of cervical cancer. They also present 10-15 years earlier with 
invasive disease compared with HIV-negative women. The possible benefit of HAART 
(highly effective antiretroviral therapy) is still unclear (reviewed in (Pantanowitz & 
Michelow)).
Sexual and reproductive factors are closely related to HPV infection and risk of 
cervical cancer. Young age at first full-term pregnancy and number of full-term 
pregnancies (FTP) have been found to be strongly associated with the risk of ICC with 
RR=1.77 (95% CI: 1.42-2.23) for first FTP at age <17 years vs. ≥25 years, and 
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RR=1.76 (95% CI: 1.53-2.02) for ≥7 vs. 1-2 FTPs. Results were similar when restricted 
to HPV positive and negative cases and controls (2006).
Lifetime number of sexual partners and age at first intercourse as risk factors for CIN3 
and invasive cervical cancer have also been studied in a collaborative re-analysis of 
epidemiological studies (2009). All analyses were conditioned on age and study (and 
study center for multicenter studies). RRs for ICC increased with increasing numbers of 
lifetime sexual partners; the RR was 2.78 (95% CI: 2.29-4.52) for ≥6 versus 1 partners, 
after additional conditioning on age at first intercourse, number of full-term 
pregnancies, and age at first full-term pregnancy. RRs for ICC increased with 
decreasing age of first intercourse, showing an RR=2.05 (95% CI: 1.54-2.73) for age 
≤14 years vs. ≥25 years, conditioned on number of lifetime sexual partners and 
reproductive factors as above. Interestingly, conditioning on reproductive factors 
strongly attenuated the RR for age at first intercourse. This latter factor was closely 
linked to age at first full-term pregnancy in many studies. However, an association 
between age at first intercourse and ICC was also seen for nulliparous women. The 
increased risk of ICC conferred by numerous sexual lifetime partners and low age at 
first sexual intercourse is most likely related to the risk of acquiring HPV infection and 
potential duration of that infection, since many young women acquire HPV infection 
soon after sexual debut (Winer et al; Winer et al, 2005).
Factors related to sexual partners of women also play an important role for the risk of 
CIN and ICC. A Spanish study including husbands of women involved in two case-
control studies of CIN showed that the risk of ICC was strongly related to the 
husband’s number of lifetime sexual partners, but especially to the number of sexual 
partners during marriage (adjusted OR 11.0 (95% CI: 3.0-40.0) for >21 vs. 1 woman) 
and to the number of prostitutes as extramarital sex partners (adjusted OR 8.0 (95% 
CI:2.9-22.2) for >10 women vs. none). Young age at first intercourse also increased the 
risk of ICC. A strong association was also seen for penile HR-HPV infection in the 
husband, especially for type 16, and ICC (Bosch et al, 1996). The finding in this study 
of similar figures when restricting the analyses to husbands whose wives were 
monogamous underscores the role of men as vectors of HPV infection. A pooled 
analysis of the IARC HPV Prevalence studies also found an increased prevalence of 
HPV infections related to the husband’s extramarital affairs after correcting for lifetime 
number of sexual partners of the woman and her age (OR 1.45: CI 95%, 1.24-1.70) 
(Vaccarella et al, 2006). The importance of male sexual behavior for HPV infection is 
also underscored by a study from Pakistan, showing stronger association with the 
husband’s extramarital affairs and with the age difference between husband and wife 
than with number of lifetime sexual partners of the woman (Raza et al).
Male circumcision has been proven to reduce prevalence and incidence and to increase 
clearance rates of male genital HPV infection (Auvert et al, 2009; Gray et al; Tobian et 
al, 2009). It also reduces the prevalence and incidence of HPV infections in their 
female partners (Wawer et al). Among men with multiple partners it decreases the risk 
of ICC in their partner (Castellsague et al, 2002). However, the protective effect is only 
partial.
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Condom use is protective against HPV transmission, though not completely (briefly 
discussed further in 2.4.1.). Non-use/ low use of condoms is often taken into account as 
a potential confounding risk factor when studying other factors.  
Smoking has been defined as a carcinogen in cervical cancer by the IARC (2004). The 
International Collaboration of Epidemiological Studies on Cervical Cancer combined 
data from 23 epidemiological studies on the relation between smoking and 
development of ICC. Current smokers had an increased risk of SCC compared with 
never smokers (RR: 1.60 CI: 1.48-1.73). This relation was stronger with lower age for 
smoking onset and dose. The increased risk was still present, but weaker, for former 
smokers. Considering only HR-HPV positive women, the risk of SCC was still 
significantly increased for current smokers. No relation between smoking and ADC 
could be demonstrated (Appleby et al, 2006). The role of smoking as an independent 
risk factor for SCC was confirmed by a Nordic epidemiologic study (Kapeu et al,
2009). Moreover, a prospective study of young women, controlling for cervical HPV 
status (Birmingham, UK), showed that smoking increases the risk of developing CIN2 
or 3 after becoming sexually active (Collins et al). Smoking has been reported to impair 
antibody response to HPV infection (Simen-Kapeu et al, 2008).
A collaborative re-analysis of 24 studies dealing with oral contraceptives as a risk 
factor for cervical cancer showed an increased risk for cervical cancer, with a relative 
risk of 1.90 (95% CI: 1.69-2.13) for use >5 years versus ‘never use’ (Appleby et al,
2007). This effect was independent of HR-HPV status. However, risk decreases with 
time from last use to a level comparable with that of ‘never users’ after 10 years. 
Estimation of long-term risks of oral contraceptives (10 years’ use) shows only small 
increases in cumulative incidence, at least if use is limited to younger age groups. The 
mechanism by which oral contraceptive use is linked to cervical cancer is not fully 
understood.  
Increased risk of cervical cancer has been observed for women with low socioeconomic 
status. Studies indicate that the relation between low socioeconomic status and 
CIN3/ICC is due to confounders, such as HPV infection, age, study center, sexual 
behavior, and husband’s sexual behavior (including sexual contact with prostitutes), 
history of cervical screening, and smoking (de Sanjose et al, 1997; Khan et al, 2005).
One study hypothesized that the sexual behavior of men is a major contributor to 
increased risk of ICC for these women, based on the observed high rate of risky sexual 
behavior among men in this group (de Sanjose et al, 1997).
Sexually transmitted infections other than HPV have been suggested as risk factors of 
ICC. In pooled analyses of Herpes simples virus-2 (HSV-2) , HSV-2 seropositivity was 
associated with an increased risk of ICC among HPV-positive women after adjustment 
for potential confounders, suggesting that HSV-2 may act in conjunction with HPV to 
modestly increase the risk of ICC (Castellsague et al, 2006; Smith et al, 2002).
However, a Nordic longitudinal nested case-control study used 1974-1993 data and 
compared those results with results from a meta-analysis of studies. Smoking and HPV-
adjusted analyses showed no association of HSV-2 with ICC (Lehtinen et al, 2002). In 
a study conducted in Jamaica, analyses adjusted for potential confounders including 
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HPV status showed no association of either HSV-2 or Chlamydia Trachomatis (CT) 
with grade of cervical lesion (CIN3+ vs. CIN1) (Castle et al, 2003).
More consistent positive correlations with cervical cancer have been seen for CT. One 
population-based case-control study found that the relative risk of ICC associated with 
past CT infection was 17.1 (95% CI: 2.6 to infinity), after adjustment for HPV-
infection (Wallin et al, 2002). A pooled analysis of the IARC multicentric case-control 
study on CT and ICC found an increased - yet much more modest - risk of CT for SCC 
(OR 1.8: 95% CI, 1.2-2.7) but not for adeno- or adenosquamous carcinoma (Smith et 
al, 2004). More recent results have lead to similar conclusions (Madeleine et al, 2007).
A study carried out in Taiwan, with prospective follow-up of women for 9 years, found 
no statistically significant overall risk of ICC, but a significant association with incident 
ICC (OR 2.9, 95% CI, 1.2-7.4) (Naucler et al, 2007a). The overall general impression 
from studies is that a modest effect of CT on ICC is plausible. However, a recent study 
showed no association between CT and CIN2+, arguing that previous results may have 
been related to an increased susceptibility to HPV infection caused by CT (Safaeian et 
al).
HSV-2 and Chlamydia Trachomatis may act as cofactors in development of ICC.  This 
concept is more questionable for HSV-2 than for CT. The failure to detect them in 
tumors or prediagnostic cervical smears suggests that the effect comes early in 
carcinogenesis (Naucler et al, 2007a; Tran-Thanh et al, 2003). CT has been shown to 
increase expression of the proliferation marker Ki-67 antigen in cervical epithelium, 
and interfere with growth factor signaling (Fischer, 2002). There are also findings to 
support that CT possesses effective mechanisms to evade adaptive immunity. 
Chromosomal aberrations are increasingly common with progressive disease and 
have been found in 19% of CIN1and 90% of CIN3 lesions (Wentzensen & von 
Knebel Doeberitz, 2007). Observed chromosome losses include 2q,3p, 4p, 4q, 6q, 
11q, and 18q, while those gained include 1q, 3q, 5p, and 8q (Duensing & Münger, 
2004). The most consistently noted aberration is gain of chromosome 3q and along 
with it, genomic amplification of the RNA component of the human telomerase gene 
(hTERC), which resides on cytoband 3q26 (Heselmeyer et al, 1997; Heselmeyer et 
al, 1996). Genomic amplification of this gene is therefore likely to play an important 
role in progression from low-grade dysplasia to high-grade CIN and invasive cancer.
In a previous study, progression was never observed in the absence of genomic 
amplification, and, inversely, extra copies of this gene were not present in lesions that 
spontaneously regressed (Heselmeyer-Haddad et al, 2005). This marker has shown 
promise to be highly sensitive and specific for identification of CIN3 and ICC 
(Andersson et al, 2009) and evaluation in large-scale screening is planned.  
A genetic link to cervical cancer was first demonstrated in a Swedish epidemiological 
study published in 1999, showing a familial clustering of this disease specific to 
biologically related individuals. For example, there was an increased risk of ICC for 
biological mothers of cases compared with controls, whereas there was no difference in 
risk for adoptive mothers (Magnusson et al, 1999).  One suggested genetic factor is a
polymorphism at codon 72 of the p53 gene, resulting in either proline or arginine. Some 
researchers have seen increased risk of HPV–induced carcinogenesis in homozygous 
individuals, but study results have been somewhat conflicting (Andersson et al, 2001; 
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Bertorelle et al, 1999; Oliveira et al, 2008). Genetic variations related to adaptive 
immunity factors such as major histocompatibility complex class polymorphisms and 
cytokine signaling have also been suggested as contributive risk factors in HPV-
associated carcinogenesis (Ghaderi et al, 2000) .
Nutritional factors have also been suggested to play a role in acquisition of HPV 
infection and carcinogenesis. A prospective study (24 months) of women at risk of 
HPV infection investigated the possible protective effects of folate (folic acid) for HPV 
infection, while controlling for vitamins B12, A, E, and C and total carotene, as well as 
taking into account known risk factors. Higher folate status was inversely related to the 
risk of acquiring HPV infection and individuals with higher folate status were more 
likely to be associated with becoming HPV–test negative during the follow-up time.  
Protective effects against CIN have also been observed for folate, as well as for 
riboflavin, thiamine, and vitamin B12 (Hernandez et al, 2003). High intake of fruits and 
vegetables, as well as specific micronutrients such as B vitamins including folate, 
appear to be associated with protective effects against persistent HPV infection and 
cervical carcinogenesis, though this field needs further study to establish robust 
evidence (Garcia-Closas et al, 2005).
A case-control study conducted in Honduras among women of low socioeconomic 
status, and taking into account HPV infection and additional risk factors for cervical 
cancer, showed an independent increase in risk from chronic (>35 years) exposure to 
wood smoke from wood fires in the kitchen (OR 9.42 (95% CI, 1.16-7.74) (Velema et 
al, 2002). The relationship was dose-dependent. Since wood smoke exposure is 
significant for many women in developing countries, this association merits further 
investigation.  
2.4 A preventable disease 
The well-known infectious etiology and associated risk factors, the availability of 
prophylactic HPV vaccines, and the usual 10-20 years required for detectable and 
easily treatable precancerous lesions to progress into invasive cancer, all offer excellent 
prospects for prevention of cervical cancer.  
2.4.1 Behavioral prevention strategies 
Primary prevention of cervical cancer means prevention of HPV infection and cofactors 
known to increase the risk of cervical cancer. Education is needed to improve 
knowledge about the disease, in order to reduce risky sexual behavior. Strategies to 
achieve less risk-taking behavior need to be adapted to local context. Moreover, cancer 
control programs should include efforts to reduce smoking, a known risk factor for 
cervical cancer and other cancers (2006 ). Early smoking initiation has also been 
associated with more lifetime sexual partners, earlier sexual debut, younger age at first 
pregnancy, and less condom use compared with never smokers, suggesting that this 
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group represents a target for health information (Hansen et al). Primary prevention 
through HPV vaccination is discussed in the following section. 
  
Risky sexual behavior with a high number of sexual partners or concurrent sexual 
relationships is not necessary for HPV transmission. HPV infection is the most 
common STI and is prevalent even among individuals with few sexual partners. 
However, the risk of becoming infected depends on various factors. In countries where 
early marriage is customary, girls/young women commonly have their sexual debut at 
an earlier age than boys/men. Men spend more of their sexually active lives unmarried, 
and premarital sexual relations are more common among men than women. Hence, 
women may be at risk of HPV exposure even if they only have sex with their husband. 
A global trend is rising age at first marriage, and more widespread premarital sexual 
relationships among both men and women. Overall, single men report more numerous 
sexual relationships than do single women – however it is unclear whether bias in 
reporting contributes to these differences. Generally, among all sexually active men and 
women, men tend to report multiple sexual partners more frequently than women. In 
summary, these patterns suggest that men are a source of STIs, even within marriage. It 
is not only individual behavior that affects risk of HPV infection and other STIs, but the 
position of the individual in a sexual network (reviewed in (Bosch et al, 2008).
Consistent male condom use has proven to partially protect the female partner from 
HPV infection. Protective effects against CIN have also been observed (Veldhuijzen et 
al; Winer et al, 2006). Condom use is an attractive option to prevent HPV transmission, 
since it also protects against other STIs, including HIV, which is a risk factor for early, 
aggressive cervical cancer (2006 ).
In men, most HPV infections seem to clear within one year (reviewed in (Burchell et 
al, 2006)), with a mean duration of infection of about 7.5 months and 12.1 months for 
HPV 16 (Giuliano et al). Education to achieve increased awareness about the male role 
in HPV transmission, as well as recommendations for preventive measures, may also 
be one way to involve men in protecting women from future cervical cancer. 
  
2.4.2 HPV vaccination 
Technical advances in the 1990s enabled successful production of the major viral 
capsid protein L1 in eukaryotic expression systems. The ability of the L1 protein to 
self-assemble into highly immunogenic virus-like particles (VLPs) was also 
demonstrated (Kirnbauer et al, 1992; Zhou et al, 1991).  Natural HPV infection does 
not elicit strong immune responses, but about 50-70% of women with incident HPV 
infection seroconvert within 18 months. Type-specific variation showed lower 
seroconversion levels for HPV 16 and 18 than for HPV 6  (Carter et al, 2000).  In many 
women, low levels of anti-L1 antibodies are present several years after infection (af 
Geijersstam et al, 1998).
Today, one quadrivalent vaccine against HPV 16, 18, 6, and 11 (Gardasil, by Merck 
and Co, Inc) and one bivalent vaccine against HPV 16 and 18 (Cervarix, by 
GlaxoSmithKline Biologicals) are available on the market. Incorporation of HPV 
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vaccination of young girls 10- 12 years into the vaccination program, and catch-up 
vaccination of girls aged 13-17 years began in 2010. In Sweden, a central decision was 
made to use Cervarix, though this question is still under debate.  
Both vaccines are given by intramuscular injection, with three doses given within 6 
months. Delivered via the intramuscular route, both vaccines elicit a strong immune 
response compared with natural infection, and result in nearly 100% protection against 
incident HPV infection with the HPV types found in the vaccine (reviewed in 
(Stanley)). 
For Gardasil, effective protection against CIN caused by vaccine HPV types has been 
documented. Such protective effects have also been shown among women with 
seropositivity for vaccine HPV types and simultaneous HPV DNA negativity, 
indicating protection against disease caused by re-infection or re-activation of latent 
infection (Olsson et al, 2009). Effective protection is also seen against vulvar and 
vaginal intraepithelial neoplasia (VaIN/VIN) and external condylomas caused by any 
of the vaccine HPV types. An RCT on the effects of Gardasil on HPV-associated 
genital disease in women aged 16-26 years at enrollment, with an average follow-up 
time of 3.6 years, was published in 2010. In women negative for 14 HPV types (12 HR-
HPV types and LR-HPV 6 and 11) who had received at least one vaccine dose, the 
reduction of HPV 16/18/6 or 11-related disease was 98% for CIN1, 100% for CIN2, 
CIN3, and AIS, 96% for genital warts, and 95% for VaIN/VIN1 and VaIn/VIN1-3. In 
the intention-to-treat-population (HPV-exposed and non-exposed), the reduction of 
HPV 16/18/6 or 11-related disease was 69% for CIN1, 55% for CIN2, 45% for CIN3, 
60% for AIS, 80% for genital warts, and 76-79% for VaIn/VIN. Considering genital 
lesions caused by any HPV type, reduction of incident genital disease rates among the 
population negative for 14 HPV types were: CIN 1+ 29%, CIN2+ 43%, genital warts 
83%, and VaIN/VIN2-3 77%. In the intention-to treat-population, the reduction of 
incident genital disease rates caused by any HPV type were as follows: CIN1+ 19%, 
CIN2+ 19%, genital warts 62%, and VaIN/VIN2-3: 50% (Munoz et al).
For Cervarix, an RCT enrolling 15-25 year old girls/women, with average follow-up of 
almost three years, also showed a high degree of efficacy against CIN2+ related to 
HPV 16 and 18 and to nonvaccine HPV types (Paavonen et al, 2009). In a cohort of 
women (irrespective of HPV status) who had received at least one vaccine dose, HPV 
16 or 18-related CIN2+ was reduced by 53% and CIN3+ by 34%. For CIN2+ related to 
any HPV type, the reduction was 30%, and for CIN3+ 25%. In a cohort of women 
naive for 14 HPV types who had received at least one vaccine dose, HPV 16 or 18-
related CIN2+ was reduced by 98% and CIN3+ by 100%. For CIN2+ related to any 
HPV type, the reduction was 87%. Cross-protection has also been seen against CIN2+ 
caused by HPV 31, 33, and 45. Significant cross-protection against persistent infection 
with non-vaccine HPV types has been seen for both vaccines (Lu et al).
In summary, the two prophylactic HPV vaccines are safe, well-tolerated (Lu et al;
Wacholder et al), and effective in preventing HPV infections and lesions associated 
with vaccine HPV types in young women (Lu et al; Munoz et al; Paavonen et al,
2009). In a perfect world, the current HPV vaccines may prevent up to 70-76% of all 
ICC (de Sanjose et al; Li et al); about 66-70% of SCC, and about 78-82% of ADC (de 
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Sanjose et al). According to estimates of figures for high-grade precancerous lesions 
(CIN2-3/HSIL), HPV 16 and/or 18 account for about 47-67% (Clifford et al, 2006; 
Smith et al, 2007). The potential preventive effect may be even higher, depending on 
the degree of cross-protection induced against disease caused by close relatives of HPV 
16 and 18.  To achieve optimal preventive effect, the vaccine should be administered 
before sexual debut, but preventive effects have also been seen against re-infection and 
re-activation of HPV infection and associated diseases.  
Once the vaccine program is fully implemented, efficacy and safety will need to be 
followed prospectively. Given the incomplete protection against future cervical cancer 
and uncertainty regarding duration of protective effects, screening will need to continue 
in some form even in vaccinated cohorts. A major challenge will be to inform 
vaccinated individuals about the continued importance of screening (Sundstrom et al).
2.4.3 Screening – a success story 
Secondary prevention of cervical cancer involves organized screening programs to 
target the appropriate age group, as well as effective links between all levels of care, 
including appropriate follow-up for diagnosis and treatment of women with positive 
screening results (2006 ).
 
2.4.3.1 History of cervical screening 
Since the middle of the last century, cervicovaginal cytology screening with 
Papanicolau (Pap) smears has been used in many regions worldwide, saving lives of 
millions of women. The method is named after its innovator, Dr. Papanicolau, born in 
Greece in 1883. He was a physician with a many talents. The idea of taking vaginal 
smears emanated from his research that involved collecting oocytes from guinea pigs. 
In order to evaluate timing of ovulation, Dr. Papanicolau started analyzing cells 
collected with vaginal smears. In the 1920s he started analyzing vaginal smears from 
humans. When he first observed malignant cells in a vaginal smear he realized that he 
had made an important discovery. However, the scientific community showed little 
interest in the method (reviewed in (Michalas, 2000)). The breakthrough did not come 
until 1941, after many years of observation and robust correlation with cervical cancer 
(Papanicolau GN, 1941). In this paper, Dr. Papanicolau emphasized the need for a 
simple inexpensive method that could be applied to large numbers of women for early 
diagnosis of cancer. 
2.4.3.2 Cytological evaluation and classification 
The rationale for cytological screening to prevent cervical cancer is as simple as it is 
ingenious. By evaluating cells collected from the cervix, precancerous lesions in 
asymptomatic women can be identified and treated, thereby interrupting the possible 
progressive evolution of the lesion toward malignancy. In addition the procedure may 
identify women who have already developed invasive cancer at an early stage, which 
improves prospects of successful treatment.  
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Most abnormalities detected in cytological screening are subtle and non-specific, with a 
low positive predictive value for detection of CIN2+ and CIN3+. There is also a high 
degree of interobserver variability in cytological assessment, resulting in highly 
variable test accuracy (Fahey et al, 1995; Scott et al, 2002).  Pronounced cytological 
abnormalities are highly specific, with high positive predictive value for such lesions. 
However, sensitivity of cytology screening to detect precancerous lesions is limited, 
with a high degree of variation between screening clinics, cytolopathologists and 
cytotechnologists (Cuzick et al, 2008).
  
Different cytological classification systems exist. The Swedish classification system 
can easily be translated into the Bethesda classification system (Solomon et al, 2002),
the most commonly used system in the scientific community today (Table 2.3). About 
600 000-700 000 cytology smears are sampled every year, of which 57-70% are carried 
out under the population-based screening program. About 80% of all abnormal smears 
are non-specific low-grade abnormalities (ASCUS, AGUS/AGC or LSIL), and only 
20% are diagnosed as the high-grade abnormalities (ASC-H, ACG-H or HSIL) that 
usually account for histologically verifiable high-grade lesions (Sparén, 2008).
Summary of the Besthesda 2001 system  
Specimen adequacy:  
Satisfactory for evaluation (including statement on 
presence/absence of endocervical cells)  
Unsatisfactory for evaluation  
Interpretation:  
Negative for intraepithelial lesion or malignancy  
Epithelial cell abnormality:  
Squamous cell  Glandular cell  
ASC-US (atypical squamous 
cells of undetermined 
significance  
AGC (specify endocervical, 
endometrial or not otherwise 
specified)  
ASC-H (atypical squamous 
cells cannot exclude HSIL)  
AGC-H (atypical glandular 
cells, favor neoplastic)  
HSIL (high-grade squamous 
intraepithelial neoplasia)  
AIS (endocervical 
adenocarcinoma in situ)  
Squamous cell carcinoma  Adenocarcinoma  
Table 2.3. Cytological classification according to a summarizd version of the Bethesda 2001 terminology 
(Solomon et al, 2002).
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2.4.3.3 Follow-up and treatment 
Following an abnormal screening result, the gold standard investigation to diagnose 
CIN includes a pelvic examination by a specially trained clinician (colposcopist), 
colposcopic assessment of the cervix and vaginal fornices, biopsy of suspected lesions, 
and endocervical brush sample for endocervical sampling, alternatively endocervical 
curettage if the patient is under anaesthesia. Colposcopy involves microscopic 
examination of the cervix, before and after application of acetic acid and iodine (2006 ; 
Andrae B, 2010). The colposcopist assesses for the presence of acetowhite areas 
including punctuation and mosaic appearance, presence and characteristics of epithelial 
capillaries, size of visible lesions, and iodine uptake (Walker et al, 2003). The 
examination should determine the location of the transformation zone and identify 
suspected precancerous and cancerous lesions. In relevant cases, a decision should be 
taken about the most suitable treatment depending on patient characteristics such as 
age, fertility status, desire for future pregnancy, and risk profile (2006 ; Andrae B, 
2010; Wright et al, 2007b).
Colposcopy complemented with biopsy and histological assessment is a gold standard 
examination with certain disadvantages. Performance of colposcopy is highly variable 
between examiners. In one study involving seven colposcopists, sensitivity for 
detection of histologically verified CIN3+ varied from 29 to 93% 
(p=<0.001).Sensitivity increased with the number of biopsy samples, up to 4 “random” 
biopsies, and with endocervical curettage in 6/7 colposcopists (Pretorius et al), thus 
underlining the risk of sampling error. There is strong scientific support for random 
biopsies and endocervical sampling in absence of visually obvious pathology (reviewed 
in (Chase et al, 2009)). Both over- and underdiagnosis in histological evaluation may 
occur and are most pronounced with less advanced lesions (Carreon et al, 2007).
If a diagnosis of CIN2 or CIN3 is made by histological assessment, surgical removal of 
the lesion is always indicated in cases of CIN3, while there are exceptions in CIN2 (see 
below). In cases of histological findings of CIN1, treatment is indicated in HR-HPV 
positive women who are not likely to plan future pregnancies. A relative indication for 
treatment of CIN1 is persistent CIN1 for >2 years and a direct indication in women >40 
years (Andrae B, 2010). 
Side-effects are associated with treatment of CIN. A Cochrane review published in 
2010 assessed CIN treatment options including laser conization, large loop excision of
the transformation zone (LLETZ), knife conization, cryotherapy, and laser ablation in 
regard to residual disease detected on follow-up examination, severe perioperative pain, 
severe primary and secondary bleeding, cervical stenosis at follow-up, vaginal 
discharge, incomplete colposcopy at follow-up, extent of thermal artifact histological 
specimen, and duration of treatment. The authors concluded that no technique is 
obviously superior to other in terms of treatment failure or operative morbidity, but 
LLETZ appeared to provide the most reliable histological specimen with the least 
morbidity (Martin-Hirsch et al). A major drawback of ablative methods is that no tissue 
specimen is available for histological analysis.  
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Moreover, prior treatment of CIN requires long-term follow-up due to the increased 
risk of future CIN3 and cervical cancer (Melnikow et al, 2009; Strander et al, 2007b).
The risk is particularly high in women treated with cryotherapy (Melnikow et al, 2009; 
Strander et al, 2007b). Treatment of CIN is also associated with increased risk of 
perinatal morbidity and mortality. A meta-analysis studied the effect of different 
excisional and ablative CIN treatment techniques on perinatal mortality, preterm 
delivery, and low birth weight. The highest risks are seen for cold knife conization. 
Destruction using laser ablation and cryotherapy is associated with fewer perinatal side-
effects than excisional techniques (Arbyn et al, 2008b). Ablative methods are second 
line therapy according to Swedish guidelines (Andrae B, 2010). They are considered 
suitable only if the histological result from a colposcopically directed biopsy confirms 
suspicion of CIN2, and invasive disease can be excluded beyond all reasonable doubt, 
and in women with an overt or assumed desire to become pregnant in the future. In 
young women with CIN2, a wait and see approach is an alternative due to the high rate 
of spontaneous regression in this group. Women younger than 40 years diagnosed with 
persistent CIN1 should not be treated, but followed-up (2006 ; Andrae B, 2010; Wright
et al, 2007a).
Management guidelines for CIN treatment are based on a relatively crude estimate of 
future cancer risk; overtreatment is significant since many of the lesions that are treated 
would have regressed spontaneously. Improved knowledge of prediction of progression 
and invasion is needed to minimize side-effects of screening, follow-up, and treatment 
of potentially precancerous lesions. Therapeutic vaccination (e.g. against viral 
oncoproteins) represents an attractive option. Experiments in animals and humans have 
generally shown a high tolerability for these vaccines, a few of which have also 
induced significant immune responses. Proof of clinical efficacy in premalignant and 
malignant disease in humans is still limited (Decrausaz et al; Trimble & Frazer, 2009), 
but some vaccines have induced regression of CIN in a large percent of patients (van 
der Burg et al).
  
2.4.3.4 Preventive effects of conventional cytology screening in Sweden   
Previous studies have shown that, although insufficient participation in screening and 
poor management of abnormal screening findings are major contributors to cervical 
cancer in Sweden, some cancer cases develop in spite of previous normal screening 
results (Andersson-Ellstrom et al, 2000; Stenkvist & Soderstrom, 1996). Reliability of 
cytological screening therefore depends on repeated sampling.  
In Sweden, a population-based screening program was progressively established in the 
1960s and 1970s. Today, women are invited to participate in screening from the year 
they turn 23 years, then every three years until the age of 50, after which screening is 
scheduled every five years until age 60. Screening has been successful, reducing 
incidence of SCC by about two thirds and overall cervical cancer-induced mortality 
even more (Bergstrom et al, 1999; Gunnell et al, 2007). The incidence of ADC, 
however, has increased since initiation of the screening program despite an increase in 
the number of cases of adenocarcinoma in situ (AIS) found by screening (Gunnell et al,
28
Moreover, prior treatment of CIN requires long-term follow-up due to the increased 
risk of future CIN3 and cervical cancer (Melnikow et al, 2009; Strander et al, 2007b).
The risk is particularly high in women treated with cryotherapy (Melnikow et al, 2009; 
Strander et al, 2007b). Treatment of CIN is also associated with increased risk of 
perinatal morbidity and mortality. A meta-analysis studied the effect of different 
excisional and ablative CIN treatment techniques on perinatal mortality, preterm 
delivery, and low birth weight. The highest risks are seen for cold knife conization. 
Destruction using laser ablation and cryotherapy is associated with fewer perinatal side-
effects than excisional techniques (Arbyn et al, 2008b). Ablative methods are second 
line therapy according to Swedish guidelines (Andrae B, 2010). They are considered 
suitable only if the histological result from a colposcopically directed biopsy confirms 
suspicion of CIN2, and invasive disease can be excluded beyond all reasonable doubt, 
and in women with an overt or assumed desire to become pregnant in the future. In 
young women with CIN2, a wait and see approach is an alternative due to the high rate 
of spontaneous regression in this group. Women younger than 40 years diagnosed with 
persistent CIN1 should not be treated, but followed-up (2006 ; Andrae B, 2010; Wright
et al, 2007a).
Management guidelines for CIN treatment are based on a relatively crude estimate of 
future cancer risk; overtreatment is significant since many of the lesions that are treated 
would have regressed spontaneously. Improved knowledge of prediction of progression 
and invasion is needed to minimize side-effects of screening, follow-up, and treatment 
of potentially precancerous lesions. Therapeutic vaccination (e.g. against viral 
oncoproteins) represents an attractive option. Experiments in animals and humans have 
generally shown a high tolerability for these vaccines, a few of which have also 
induced significant immune responses. Proof of clinical efficacy in premalignant and 
malignant disease in humans is still limited (Decrausaz et al; Trimble & Frazer, 2009), 
but some vaccines have induced regression of CIN in a large percent of patients (van 
der Burg et al).
  
2.4.3.4 Preventive effects of conventional cytology screening in Sweden   
Previous studies have shown that, although insufficient participation in screening and 
poor management of abnormal screening findings are major contributors to cervical 
cancer in Sweden, some cancer cases develop in spite of previous normal screening 
results (Andersson-Ellstrom et al, 2000; Stenkvist & Soderstrom, 1996). Reliability of 
cytological screening therefore depends on repeated sampling.  
In Sweden, a population-based screening program was progressively established in the 
1960s and 1970s. Today, women are invited to participate in screening from the year 
they turn 23 years, then every three years until the age of 50, after which screening is 
scheduled every five years until age 60. Screening has been successful, reducing 
incidence of SCC by about two thirds and overall cervical cancer-induced mortality 
even more (Bergstrom et al, 1999; Gunnell et al, 2007). The incidence of ADC, 
however, has increased since initiation of the screening program despite an increase in 
the number of cases of adenocarcinoma in situ (AIS) found by screening (Gunnell et al,
29
2007). The protective effect of cervical cytology screening against ADC has been 
called into question (Dahlstrom et al).
A nationwide audit of the Swedish screening program was recently undertaken, 
including all adequately reported cervical cancer cases diagnosed 1999-2001 (n=1230) 
and five age-matched controls per subject (Andrae et al, 2008). Results showed that 
non-participation was associated with an increased risk of developing non-squamous 
cervical carcinoma (mainly ADC) with OR 1.59 (95% CI: 1.30-2.11), whereas the 
corresponding figure for SCC was 2.97 (95% CI: 2.51-3.50). These results argue for a 
weaker but nevertheless protective effect of screening even for ADC. The increased 
risk of non-participation in screening was seen in all age groups (21-29, 30-65, and >66 
years). Non-participation was also associated with a higher risk of presenting with an 
advanced cancer stage (FIGO IA: OR 1.70, 95% CI, 1.28-2.26; FIGO IB: OR 2.10 95% 
CI, 1.71-2.59; FIGO ≥II 4.84, 95% CI, 3.61-6.44). 
These results are supported by an analysis comparing the characteristics of a 
prescreening and screening cohort of women treated for cervical cancer at 
Radiumhemmet Oncology Clinic in Stockholm, Sweden, during the periods 1944-1957 
and 1990-2004 respectively.  In the screening cohort, women were older (mean age 55 
vs. 49 years) with a larger portion of women older than 69 years (27% vs. 5%) 
compared with the prescreening group. In the prescreening cohort, only a minority of 
patients presented with early stage (FIGO stage I) cancer (17%) whereas in the 
screening cohort 55% of cases were early cancers. Adenocarcinoma comprises a
proportionally larger group in the screening cohort compared with the prescreening 
cohort (26% vs.5%) (Accepted in International Journal of Gynecological Oncology 
(Pettersson Folke, 2011)).  
Inadequate management of abnormal smears is relatively common in the history of 
women diagnosed with cervical cancer in spite of screening participation. This is 
particularly common for low-grade cytological abnormalities, among which a 
significant number of all high-grade precancerous lesions are detected (Kinney et al,
1998) . Repeated cytology has been proven to be an inadequate strategy for follow-up 
of low-grade abnormalities. Women with low-grade abnormalities are at increased risk 
of cervical cancer. Histological assessment leads to a reduced risk compared with cases 
managed with repeat cytology alone (OR: 0.46, 95% CI, 0.24-0.89) (Silfverdal et al;
Stenkvist & Soderstrom, 1996).
In conclusion, non-participation in cervical screening and inadequate follow-up and 
treatment of abnormal screening findings are major reasons why women develop 
cervical cancer and advanced disease with ensuing high mortality. Screening coverage 
in Sweden is 70-80%, with significant variation among different regions (Sparén, 
2008). The aim set by the European Union is to reach at least 85% screening coverage. 
However, no EU country has achieved this goal through organized screening; coverage 
varies from 10-79% (Anttila et al, 2009). Improving screening coverage and clinical 
management of women with abnormal screening results can further reduce cervical 
cancer incidence and mortality even in countries with established organized population-
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Today, a variety of screening methods and strategies exist, many of which are related to 
detecting the presence of HR-HPV infection (see 2.5). During 2010, prophylactic HPV 
vaccination was incorporated into the Swedish vaccination program for girls aged 10-
12 years along with catch-up vaccination for girls aged 13-17 years. Up to this point in 
time, vaccination of girls up to 17 years was subsidized, but not free of charge.  Within 
six years, cohorts of vaccinated young women will reach screening age and strategies 
will have to be adapted to fit this new situation.  
2.5 Alternative screening options 
2.5.1 Liquid-based cytology 
Liquid-based cytology was developed as an alternative cytology method and several 
different brands are commercially available. The method is described in section 4.2.2. 
In some parts of the world, e.g. the US and the UK, LBC is the predominant cytology 
method in use. 
One advantage of LBC is that after cytology slide preparation, supplementary analysis 
can be carried out, such as reflex HPV testing for high-risk human papillomavirus (HR-
HPV) DNA. Detection of HR-HPV can distinguish between nonspecific minor 
cytological abnormalities and abnormalities that may be associated with a high risk of 
current or future CIN2+ (Arbyn et al, 2006; Froberg et al, 2008). The number of 
abnormal cytology findings can thereby be reduced, allowing healthcare resources to be 
allocated to women who may better benefit from follow-up and treatment.
Moreover, several studies have shown that LBC reduces the rate of unsatisfactory 
screening samples (Davey et al, 2007; Kirschner et al, 2006; Ronco et al, 2007a; 
Strander et al, 2007a). In settings with high rates of unsatisfactory smears, this 
advantage is important, since unsatisfactory smears entail re-sampling. In Sweden, 
however, rates of unsatisfactory smears are low (1%) (Sparén, 2008) and therefore this 
advantage alone would not motivate a change to LBC in population-based screening. 
The explanation can likely be found in the fact that highly skilled midwives sample 
virtually all screening smears in Sweden, whereas in other settings screening is 
performed by more diverse categories of medical staff with less focused training and 
less experience in sampling technique.  
Previous studies have noted an increased rate of abnormal cytology findings using LBC 
compared with conventional cytology (Davey et al, 2007; Kirschner et al, 2006; Ronco
et al, 2007a; Strander et al, 2007a). Other studies have interpreted such findings as an 
indication of increased sensitivity for detection of CIN, without gold standard 
examination with colposcopy and biopsy. The question of whether LBC increases 
sensitivity for detecting precancerous lesions, including glandular lesions, is 
controversial. Previous studies of liquid-based cytology (LBC) screening performance 
have yielded contradictory conclusions. A systematic review published in 2006 (Davey
et al, 2006) investigated the relative performance of these methods, and how 
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performance was influenced by study design and quality, including factors such as 
validity, type of reference standard used, allocation of screening test, and blinded 
evaluation of reference standard. The authors concluded that study design of previous 
studies was generally poor, and only a few studies used adequate methods to compare 
tests (Bossuyt et al, 2004).  Existing data did not support superior sensitivity for CIN2+ 
detection, and authors called for large-scale RCTs with adequate reference standards 
and methodology. 
A meta-analysis with rather strict but well-motivated inclusion criteria (Arbyn et al,
2008a) concluded that LBC was not superior to CC in either sensitivity or specificity 
for detection of CIN2+. Pooled relative sensitivity, when screening tests show ASCUS 
or more advanced abnormalities, was 1.03 (95% CI, 0.97-1.09) and relative specificity 
0.91 (95% CI, 0.84-0.98). Some studies with histologically confirmed study endpoints 
have shown improved detection of high-grade lesions (CIN2+) compared with CC 
(Davey et al, 2007; Halford et al; Hussein et al, 2005; Hutchinson et al, 1999; Strander
et al, 2007a). Others found no difference or even somewhat lower positive absolute or 
relative sensitivity for LBC (Coste et al, 2003; Hutchinson et al, 1999; Mattosinho de 
Castro Ferraz Mda et al, 2004; Ronco et al, 2007a; Siebers et al, 2009; Taylor et al,
2006).
A previous Swedish RCT (not included in the meta-analysis by Arbyn et al) comparing 
performance of LBC with CC in a population-based screening setting concluded that 
the detection rate of histologically verified CIN2+ increased markedly, by about 40%, 
with LBC (Strander et al, 2007a). Such findings led to increased use of the newer 
cytology method in the Swedish screening program. Since the publication by Strander 
et al, large-scale RCTs in population-based screening settings have been carried out in 
the Netherlands (Siebers et al, 2009) and Italy (Ronco et al, 2007a). Neither of these 
studies has shown significantly improved sensitivity for CIN2+ or CIN3+. However, an 
interesting finding was that the study by Siebers et al showed a proportionally large but 
statistically insignificant increased detection rate of carcinoma (adjusted detection rate 
ratio: 1.69: 95%, 0.96-2.99). One large-scale split-sample study in Australia (Davey et 
al, 2007) concluded that LBC was somewhat more sensitive for CIN2+, with 1.29 more 
cases found per 1000 women screened. This figure is based on histological follow-up 
diagnosis of discordant screening samples and the overall detection rates of CIN2+ 
were not addressed.  
In summary, LBC facilitates supplementary analysis (e.g. HPV reflex testing), reduces 
rates of unsatisfactory screening results, and increases the rate of abnormal cytology 
findings, but the question of whether it improves diagnostic accuracy of cytology 
screening remains unclear. 
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2.5.2 Supplementary HPV testing 
2.5.2.1 Clinical relevance and diagnostic performance 
In Sweden, about 80% of all abnormal screening results are low-grade abnormalities 
(Sparén, 2008). Although the positive predictive value of low-grade cytology findings 
for detection of high-grade cervical lesions is low, a significant portion of all high-
grade cervical intraepithelial neoplasia (CIN2+) detected through screening can be 
found in this group (Kinney et al, 1998). Colposcopy with directed biopsy is the gold 
standard method for detection of CIN, and was previously (since 2001) used for follow-
up of all abnormal cervical screening results in Stockholm County Council.
Disadvantages of this strategy for minor cytological abnormalities include unnecessary 
psychological stress, risk of overdiagnosis and overtreatment with subsequent adverse 
events, and elevated healthcare costs for the rather large number of women without
clinically significant cervical lesions (Arbyn et al, 2008b; Chase et al, 2009; Freeman-
Wang et al, 2001).
The causal relationship between HR-HPV infection and cervical cancer, along with 
highly sensitive methods for HR-HPV detection, have made detection of viral DNA 
an attractive approach to distinguish clinically irrelevant minor cytological 
abnormalities from those which may be associated with an increased risk of 
developing cervical cancer  (2000; 2003a; 2003b; Andersson et al, 2005a; Arbyn et 
al, 2006; Dillner et al). The idea of this strategy is to achieve more targeted 
management by referring only those women who may actually benefit from more 
extensive work-up and treatment. This strategy is called HPV triage when used as a 
supplement to CC and entails a second patient visit for HPV sampling and testing. If 
LBC is used in screening, supplementary HPV testing can be carried out directly from 
residual material following cytology slide preparation, so-called “reflex” testing. This 
strategy does not necessitate patient recall, and reduces sampling error.  
Cytology-based triage of ASCUS and LSIL (one or more repeated cytology smears and 
re-referral to screening if cytology samples are negative, otherwise work-up including 
colspocopy) has been a widely used follow-up strategy in Sweden and in other 
countries. The observed increased risk of cervical cancer among women with minor 
cytological abnormalities in their screening history, who had cytological but not 
histological follow-up, emphasizes the limitations of this follow-up strategy (Silfverdal
et al, 2009). The low sensitivity of repeat cytology for detection of precancerous lesions 
as a follow-up method for minor cytological abnormalities is well-documented (Arbyn
et al, 2006). The role of repeat cytology for follow-up of minor cytological 
abnormalities is now insignificant or substantially reduced in current guidelines 
(Andrae B, 2010; Arbyn et al; Wright et al, 2007a).
Because of the high sensitivity and negative predictive value of HR-HPV detection 
for high-grade precancerous lesions, HPV triage has now become an uncontroversial 
approach for management of ASCUS (2003b; Arbyn et al, 2006; Cuzick et al, 2008). 
HPV triage/reflex HPV testing has not been generally recommended in cases of 
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LSIL, due to the high prevalence of HR-HPV, which leads to poor specificity for 
HPV triage in this group. Results from a meta-analysis show that overall HPV test 
positivity varies substantially among studies, but is overall significantly lower in 
ASCUS (43%: 95% CI, 40-46%, range 23-74%) than in LSIL (76%: 95% CI, 71-
81%, range 55-89%). The highest rate of HPV-positivity seen in women with ASCUS 
aged <30 but > 20 years was 72% (Arbyn et al, 2009a).  
There is increasing support for HPV triage in older women with LSIL since HPV test 
sensitivity is usually high even in this group, and important reductions of the HR-
HPV test positivity rate after age 30 improved test specificity (Arbyn et al, 2009b; 
Brismar-Wendel et al, 2009; Dillner et al; Evans et al, 2006; Froberg et al, 2008; 
Ronco et al, 2007b). A large-scale Italian trial also concluded that HPV triage using 
Hybrid Capture 2 performed better in 35-60 year old women than in 24-34 year old 
women, both for ASCUS and LSIL (Ronco et al, 2007b). An age limit of 40 years has 
also been discussed (Cotton et al).
2.5.2.2 Cost-effectiveness  
The exclusion of HR-HPV-negative women from intensive follow-up could result in 
lower costs for the Swedish screening program. Colposcopy is resource-intensive, 
and several studies have shown that it results in high costs and is associated with risk 
of adverse effects, which indicates a need for a more efficient and less aggressive 
alternative (Cantor et al, 1998; Johnson et al, 1993; Kim et al, 2002; Myers et al,
2000; Smith, 1999) 
A recent trial conducted in Stockholm, Sweden, concluded that HPV triage to follow 
up ASCUS and LSIL was equally effective as immediate colposcopy for detection of 
CIN2+. The authors observed equally high (about 80% or more), and even somewhat 
higher HPV test positivity in ASCUS compared with LSIL, in women up to 31 years 
of age.  An associated cost-effectiveness analysis showed that the least costly strategy 
for follow-up of ASCUS and LSIL was immediate colposcopy in women < 35 years 
and HPV triage in women ≥35 years (Dillner et al). A study performed in the US 
showed that reflex HPV testing in ASCUS (regardless of the woman’s age) was 
superior to both immediate colposcopy and repeat cytology (Kim et al, 2002).A 
German study concluded that HPV triage with “two follow-up visits” (as a
supplement to CC), was cost-effective compared with repeated cytology and 
immediate treatment in women with Pap III and Pap IIId (roughly corresponding to 
ASCUS and LSIL/CIN1 to HSIL/CIN2 respectively) (Sheriff et al, 2007). One cost-
effectiveness study showed that HPV “reflex” testing is more effective and less costly
than HPV triage with “two follow-up visits”, repeat cytology and immediate 
colposcopy in women with ASCUS (Kim et al, 2002). Similar results were found in 
other cost-effectiveness analyses of HPV “reflex” testing in cases of ASCUS, which 
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concluded that this strategy was cost-effective in women of all ages (Kim et al, 2005; 
Kulasingam et al, 2006). 
Since 2010, Swedish guidelines recommend immediate colposcopy with biopsy for 
management of ASCUS and LSIL for women younger than 35 years and HPV triage 
for women ≥35 years (Andrae B, 2010). However, repeat cytology was still used in 
2010 as a follow-up method in some parts of Sweden.  
2.5.3 Primary HPV testing 
A single HPV test has higher sensitivity (~96%) for detection of high-grade CIN than a 
single cervical cytology sample (50-75%), although it is somewhat less specific  
(Cuzick et al, 2006). Considering this fact, it seems logical to use the more sensitive 
test for primary screening and the less sensitive but more specific test to triage for 
further measures.    
Primary HPV testing (alone, in combination with concomitant cytology, with cytology 
triage, or repeated HPV testing to target persistent HPV infection) has gained strong 
support as a highly effective screening strategy for prevention of cervical cancer. 
Accumulating evidence from a number of large-scale RCTs shows that HPV DNA 
detection as a primary test in population-based screening, increases detection rates of 
CIN2+ and CIN3+ compared with cytology-based screening (Bulkmans et al, 2007; 
Cuzick et al, 2003; Leinonen et al, 2009; Naucler et al, 2007b; Ronco et al). According 
to a study investigating possible screening strategies using data from the Swedish trial 
by Naucler et al (including women aged 32-38 years), the gain in sensitivity from using 
a combination of primary HPV testing and cytology was limited. The authors found 
that the optimal trade-off between sensitivity and a high PPV for detection of CIN3+ 
was achieved by complementing HPV testing with cytology triage and repeated HPV 
testing in women who are HPV positive but cytology negative, at baseline (Naucler et 
al, 2009).
One British study comparing combined HPV test and cytology with cytology screening 
alone, found equal detection rates of precancerous lesions at baseline. In the second 
screening round, however, the combined resulted in a 50% lower detection rate of 
CIN3+ compared cytology alone (Kitchener et al, 2009). Additional studies have also 
found similar reductions in detection rates of CIN3+ in subsequent screening rounds 
(Bulkmans et al, 2007; Naucler et al, 2009; Ronco et al). The Italian trial by Ronco et 
al also demonstrated a significant reduction in invasive cancer incidence following 
primary HPV screening compared with conventional cytology. Similar findings were 
obtained in a study conducted in rural India in a setting that lacked organized cervical 
screening. In that study, screening with a single HPV test in women aged 30-59 years 
resulted in significant reductions in incidence of advanced cervical cancer (FIGO stage 
II or more advanced stages) and cervical cancer-related mortality compared with 
routine practice, which included information on cervical cancer and how to seek 
screening within the existing healthcare system. Screening with a single cytology 
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sample or VIA (visual inspection of the cervix with acetic acid) did not result in any 
significant benefits compared with routine practice (Sankaranarayanan et al, 2009).   
Given the high HPV prevalence among young women and the high rate of regressive 
cervical lesions, primary HPV testing in this group leads to overdiagnosis and 
overtreatment (Leinonen et al, 2009; Ronco et al, 2007b). An age limit of about 30-35 
years is probably suitable, but this may need to be reconsidered when cohorts of HPV-
vaccinated women reach screening age. HPV genotyping allows identification of type-
specific persistent infection, and may represent an attractive approach to target women 
at highest risk of high-grade CIN and future ICC. 
Prolongation of screening intervals could be considered if HPV testing is used in 
primary screening, since a negative HPV test (alone or in combination with cytology) is 
a more reliable predictor of long-term absence of high-grade CIN than cytology alone 
(Cuzick et al, 2008; Mesher et al). Cost-effectiveness studies indicate that HPV testing 
in primary screening is an attractive option in relation to today’s screening policies 
(Bistoletti et al, 2008; Goldie et al, 2004; Kim et al, 2005). 
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3 AIMS 
3.1 General aim 
The objective of this study was to evaluate liquid-based cytology (LBC) and 
supplementary HPV testing in Sweden’s current cervical cancer screening program. An 
ideal screening strategy should be: 
▪ Highly sensitive (with low risk of false negative results) to identify true precancerous 
lesions. 
▪ Highly specific (with low risk of false positive results) to avoid unnecessary 
examinations and worry for women as well as unnecessary waste of resources. 
▪ Cost-effective, i.e. costs should be reasonable in relation to health-related outcome. 
3.2 Specific aims 
3.2.1 Paper I 
The aim of this study was to compare the combination of LBC plus HPV reflex testing 
in cases of minor cytological abnormalities (LBC+ HPV testing) with conventional 
cytology (CC) in regard to their ability to identify precancerous lesions in a population-
based screening setting.
3.2.2 Paper II 
The aim of this study was to determine the value of HPV genotyping as a reflex test in 
cases of minor cytological abnormalities. 
3.2.3 Paper III 
Since prevalence of HPV infection is age-dependent, with high prevalence and low 
discriminative value among younger women, we searched for a suitable age limit for 
HPV reflex testing. The purpose was also to define the age-specific HPV infection 
spectrum before implementing prophylactic HPV vaccine in the vaccination program. 
3.2.4 Paper IV 
The purpose of this study was to assess the cost-effectiveness of HPV triage as an 
alternative follow-up strategy to immediate colposcopy with directed biopsyor repeat 
cytology alone, for management of minor cytological abnormalities.  
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4 MATERIAL AND METHODS 
4.1 Study subjects and study design 
4.1.1 Paper I  
4.1.1.1 Enrollment and management of different cohorts 
This prospective clinical trial invited women who were included in the population-
based cervical screening program at six sampling centers in suburban Stockholm to 
participate. Over the course of one year (September 2005-September 2006) women 
were assigned to screening either with conventional cytology (CC, n=4261) or with 
liquid-based cytology (ThinPrep®, Hologic, Marlborough, MA, USA) and 
supplementary HPV testing in cases where minor cytological abnormalities 
(ASCUS/LSIL) were found (LBC+ HPV testing, LBC1, n=4059). Screening methods 
were alternated every other week. To gain more experience using the new method, 
LBC+ HPV testing exclusively was performed between September and December 2006 
(LBC2, n=2016). In all, 6075 women were assigned to LBC+ HPV testing and 4216 
women to screening with CC from September 2005 to December 2006. The main 
analyses in this study were based on the results from screening these women. To 
maintain proficiency in the use of LBC, LBC+HPV testing continued at two of the six 
sampling centers (A and B), while awaiting a definitive administrative decision 
regarding choice of screening method. For the purpose of evaluating the LBC+ HPV 
testing screening strategy over time, women screened in 2007 were included (LBC3, 
n=3383) along with the 2653 women screened at these centers from 2005 to 2006.  
 
4.1.1.2  Follow-up of abnormal screening results 
Women with abnormal screening results, using ASCUS as a cut-off, were routinely 
referred to a gynecology clinic for work-up including a pelvic examination, colposcopy 
with directed biopsies of suspicious areas, and repeat Pap smear including an 
endocervical brush sample. In clinical practice blind biopsies are encouraged if there is 
any doubt regarding absence of pathology, but management may vary. Follow-up 
cytological and histological samples were assessed within the regular healthcare 
system. Clinicians had no information on which cytology method was used.  
All women with abnormal screening results were followed up for two years from the 
time of the original screening occasion. Results were retrieved via laboratory and 
medical records, supplemented with data from the Stockholm Oncology Center 
(Onkologiskt Centrum Stockholm). Within the follow-up period most women will have 
had at least one colposcopy with subsequent biopsies and treatment with conization if 
indicated. Most treated women will also have had a post-treatment follow-up visit. 
Moreover, the follow-up time falls well within one screening cycle.  
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4.1.1.3 Outcomes 
The primary endpoint of this study was detection rate of histologically confirmed 
CIN2+ (CIN grade 2 or more advanced lesions) yielded by LBC+HPV testing versus 
CC. Detection rates of CIN using CIN1+ and CIN3+ as cut-offs (CIN1 or more 
advanced lesions and CIN3 or more advanced lesions) were also compared for the sake 
of thoroughness. We compared PPV of the two different screening strategies to detect 
CIN1+, CIN2+, and CIN3+. Secondary endpoints were the rates of abnormal 
cytological findings including both high-grade cytology and low-grade cytology.  
4.1.2 Paper II 
This prospective trial evaluates HPV reflex genotyping of LBC samples from 
population-based screening showing minor cytological abnormalities. Histological 
follow-up results obtained within one year from screening were used as the reference 
standard, with CIN2+ as the primary endpoint.
Six screening units (one of which comprised two nearby clinics) in the southern 
suburbs of Stockholm participated in the study. From September 2005-September 
2006, about 4000 consecutive liquid-based cytology samples were obtained from 
routine screening. There were 149 cases of minor cytological abnormalities 
(ASCUS/AGUS n=53 and LSIL n=93). Mean age was 33 years, median age 30 years, 
and age range 22-59 years. Women with ASCUS as a screening result were older than 
women whose screening sample showed LSIL; mean ages were 35 and 31 years, 
respectively. Age ranges were 22-58 years and 22-59 years respectively. 
All women with minor cytological abnormalities were referred for gynecological 
investigation within the regular healthcare system. Follow-up guidelines recommended 
colposcopy, directed biopsies, and a repeat Pap smear including endocervical sampling. 
If no colposcopically visible lesion was seen, blind biopsies were encouraged, but 
management varied. Follow-up data were traced through medical and laboratory 
records and supplemented with data from the Stockholm Oncology Centre. All 
calculations were based on the 112 women for whom histological follow-up results 
were registered within the predefined follow-up period. 
4.1.3 Paper III 
This cross-sectional study on the age-specific HPV infection pattern in women with 
screening results showing minor cytological abnormalities included 343 cases from 
population-based screening, with 120 cases of ASCUS (including 3 cases of AGUS) 
and 223 cases of LSIL. Age data were not accessible for one ASCUS and one LSIL 
case, and therefore age was recorded for only 341 of 343 women. Mean age was 33.6 
years (median 32, range 22-60 years). Mean age of women with screening results 
showing ASCUS was 35.7 years and for women with LSIL, 32.4 years. Women with 
ASCUS were older than women with LSIL; 38% versus 21% were older than 40 years. 
Women were grouped according to age at 5-year intervals from age 20-49 years; the 
oldest women, aged 50-60 years, were placed into a single group of comparable size. 
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4.1.4 Paper IV 
4.1.4.1 Study population 
This cost-effectiveness analysis is mainly based on data from a Swedish clinical trial 
(Andersson et al, 2005a) comparing HPV triage with repeat cytology for management 
of ASCUS and LSIL, using colposcopy with directed biopsies as the gold standard.
Primary screening was performed using conventional cytology. The study group 
consisted of a total of 117 women referred for gynecological investigation because of 
screening results showing ASCUS (n=52) or LSIL (n=125). These women underwent 
repeat conventional cytology sampling, HPV testing (Hybrid Capture 2®, Digene 
Corporation), and colposcopy with at least one biopsy. The most severe lesion found on 
biopsy or in subsequent cervical cone material determined the histologic diagnosis with 
which HPV test and Pap smear results were compared. Mean age of patients was 34 
years (median: 31 years; range 23-60 years). 
4.1.4.2 Description of follow-up strategies for ASCUS and LSIL 
1. Repeat cytology (Cytology) means referral for gynecological consultation and repeat 
conventional cytology smear only. In cases of cytological abnormality, with ASCUS as 
the cut-off, women are referred for a second follow-up visit to a gynecologist for 
colposcopy with biopsy. If the follow-up Pap smear is within normal limits, the woman 
is referred back to the primary screening program for a new Pap smear three or five 
years later, depending on patient age.  
2. HPV-based triage (HPV triage) means referral for a follow-up visit to a midwife for 
HPV testing. HR-HPV-positive women are referred for a second follow-up visit to a 
gynecologist for colposcopy with biopsy. HR-HPV-negative women are referred back 
to the primary screening program. 
3) Immediate colposcopy (Colposcopy with biopsy) means immediate referral for 
gynecological examination including colposcopy and directed biopsies. If no 
colposcopically visible lesion is seen, a biopsy is taken close to the squamocolumnar 
junction at 12 o’clock. Sensitivity and specificity of this strategy are considered to be 
100%, since by definition this approach constitutes the reference examination for 
diagnosing CIN.  
The primary endpoints of these strategies are sensitivity and specificity to detect 
histologically confirmed CIN2+ lesions. 
4.2 Cytology 
Cytological diagnoses were defined using a modified Bethesda nomenclature(Solomon
et al, 2002, as shown in Table 2.3(Solomon et al, 2002). The Bethesda classification 
was modified according to Swedish recommendations that define samples with 
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koilocytosis without cellular atypia to be within normal limits (WNL). Therefore, LSIL 
only includes cases of mild dysplasia.  
In all studies including LBC (Paper, I, II and III) all cytological screening samples were 
prepared and assessed at the Department of Clinical Pathology and Cytology, 
Karolinska University Hospital Huddinge. Cytological diagnoses were determined at 
joint sign out sessions and the final classifications were made by cytopathologists 
trained in LBC interpretation (three-day course, as for cytotechnologists) and with 
previous participation in at least ten LBC sign out sessions under the supervision of a 
more experienced colleague.  
4.2.1 Conventional cytology (Paper I, IV) 
Cells were collected from the ectocervix using a wooden Ayre spatula and from the 
endocervix using a soft brush. In the conventional method, cells are smeared on a glass 
slide that is placed in an alcohol bath for cell fixation. The cells are then stained 
according to a specific protocol--the Pap method--in order to study the various 
components of the epithelium (Papanicolau GN, 1941).
4.2.2 Liquid-based cytology (Paper I, II, III) 
Liquid-based cytology has been developed as a refinement of conventional cytology. 
Sampling is similar to that of conventional cytology, except for use of a plastic spatula. 
All midwives involved in the study received training in LBC sampling. Cells were 
directly stirred into a fixative medium in a small plastic container and cytology slides 
were prepared using the ThinPrep® 2000 processor (Hologic). The processor senses the 
quantity of cells, applies them to the slide in a thin layer with a minimal amount of 
overlap, and filters away mucus, blood, and inflammatory cells that may obscure the 
cells of interest. Pap staining was carried out as for CC, with the sole exception that the 
ammonium bath concentration was five times greater to optimize color intensity, which 
was weaker for LBC than for CC with the original staining protocol.
Staff had limited experience of LBC screening at the beginning of this study, but did 
have extensive experience with conventional cytology. A split-sample study involving 
137 patients had previously been conducted to compare LBC with CC (Zhu et al,
2007). All screening samples (LBC and CC) were assessed by the same four 
cytotechnologists who had completed a three-day course in LBC interpretation held by 
the manufacturer. Before independent interpretation of LBC, all cytotechnologists 
needed to interpret at least 200 LBC samples from routine cases under the supervision 
of a more experienced colleague.  
From September 2005 to September 2006, HPV test results did not affect cytological 
evaluation. Women with any cytological abnormality were referred for gynecological 
follow-up, regardless of HPV test results. This workup allowed evaluation of HR-HPV 
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detection using LA as a reflex test in cases of minor cytological abnormalities (Froberg
et al, 2008). Beginning in September 2006, HPV test results were taken into account 
when making the final cytological diagnosis in cases of preliminary diagnosis of 
ASCUS or LSIL. The final diagnosis was considered to be LSIL in HR-HPV-positive 
samples, and considered to be WNL in HR-HPV-negative samples, unless special 
reasons were found to consider the sample to be abnormal despite HR-HPV-negativity. 
In the present paper, cases of ASCUS and LSIL identified by LBC were assessed as 
LSIL/low-grade cytology only if HR-HPV-positive, and assessed to be WNL in HR-
HPV-negative cases of minor cytological abnormalities.  
To simplify presentation of results, abnormal cytological diagnoses were sub-divided 
into low-grade cytology (ASCUS, AGC/AGUS, and LSIL) and high-grade cytology 
(ASC-H, AGC-H, HSIL and AIS).   
4.3 HPV testing 
4.3.1 HPV detection and genotyping (Paper I, II, III)   
Of the cell suspension remaining from the LBC samples, 2 ml were used for HPV DNA 
detection and genotyping. The sample was centrifuged and the cell pellet was lysed 
according to instructions in the Total Nucleic Acid Isolation kit. DNA was extracted 
using the MagNA Pure LC Robot and analyzed with the Linear Array HPV Detection 
and Genotyping Test (LA) according to manufacturer’s instructions (all procedures by 
Roche®). 
The method includes a PCR reaction of extracted HPV DNA using a pool of 
biotinylated primers that hybridize in the L1 region of the HPV genome, chemical 
denaturation of HPV DNA amplicons to single-stranded DNA, followed by 
hybridization with matching type-specific DNA probes immobilized on nylon strips, 
and detection by colorometric determination. The result is a pattern of blue lines on a 
nylon strip, which is visually read by comparing the pattern with a reference guide. 
The 37 different HPV types included in the LA test were divided into three “risk 
categories”: (1) HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, (2) 
pHR-HPV types 26, 53, 66, 68, 73, and 82, and (3) LR-HPV types or types of 
undetermined risk including 6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83,
84, IS39, and CP6108  (Munoz et al, 2003; Munoz et al, 2006). HPV types of 
undetermined risk are considered together with the LR-HPV types. 
4.3.2 HPV detection using Hybrid Capture 2 (Paper IV) 
After being used to smear cells on a glass slide for conventional cytology, the 
endocervical brush was inserted into a transport medium provided by the manufacturer 
(Digene Corporation). Specimens were tested using the Hybrid Capture II assay, 
performed according to the manufacturer’s protocol, at the Department of Virology, 
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detection and genotyping. The sample was centrifuged and the cell pellet was lysed 
according to instructions in the Total Nucleic Acid Isolation kit. DNA was extracted 
using the MagNA Pure LC Robot and analyzed with the Linear Array HPV Detection 
and Genotyping Test (LA) according to manufacturer’s instructions (all procedures by 
Roche®). 
The method includes a PCR reaction of extracted HPV DNA using a pool of 
biotinylated primers that hybridize in the L1 region of the HPV genome, chemical 
denaturation of HPV DNA amplicons to single-stranded DNA, followed by 
hybridization with matching type-specific DNA probes immobilized on nylon strips, 
and detection by colorometric determination. The result is a pattern of blue lines on a 
nylon strip, which is visually read by comparing the pattern with a reference guide. 
The 37 different HPV types included in the LA test were divided into three “risk 
categories”: (1) HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, (2) 
pHR-HPV types 26, 53, 66, 68, 73, and 82, and (3) LR-HPV types or types of 
undetermined risk including 6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83,
84, IS39, and CP6108  (Munoz et al, 2003; Munoz et al, 2006). HPV types of 
undetermined risk are considered together with the LR-HPV types. 
4.3.2 HPV detection using Hybrid Capture 2 (Paper IV) 
After being used to smear cells on a glass slide for conventional cytology, the 
endocervical brush was inserted into a transport medium provided by the manufacturer 
(Digene Corporation). Specimens were tested using the Hybrid Capture II assay, 
performed according to the manufacturer’s protocol, at the Department of Virology, 
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Karolinska University Hospital, Stockholm, Sweden.  Briefly, DNA from cervical 
cytology material was denatured and hybridized with a cocktail of 13 RNA probes to 
oncogenic HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Hybrids 
were captured with alkaline-phosphatase-conjugated antibodies specific to HPV-DNA 
hybrids. A dioxetane-based chemiluminescent substrate was added, and the resultant 
relative light units (RLUs) were measured in a luminometer. Specimens with RLUs 
equal to or above the mean RLUs of triplicate positive control samples containing 1 pg 
of HPV DNA/microliter (about 5000 copies of the HPV genome) were designated as 
positive (Peyton et al, 1998).
4.4 Histology (Paper I, II, IV) 
All histological specimen (cervical biopsies and cones) were evaluated within routine 
practice. The histopathological diagnoses were established according to the CIN 
classification (Richart, 1969; Richart & Barron, 1969) , see section 2.3.6. 
4.5 Cost-effectiveness analysis of HPV triage (Paper IV) 
Base case values (Table IV:1) used in the model were mainly based on data from the 
clinical trial by Andersson et al (Andersson et al, 2005b) and supplemented with data 
from published meta-analyses on the accuracy of HPV triage for detection of CIN2+ 
(Arbyn et al, 2004; Arbyn et al, 2009a; Arbyn et al, 2005; Arbyn et al, 2006).
We used recent cost data to reflect today’s cost for follow-up within the Swedish 
healthcare system. Average unit costs for the different cost quantities (Table IV:2) were 
collected from local and national sources in Sweden. All costs were estimated in 2008 
Swedish Kronor (SEK) based on Patient-level Clinical Costing (known as cost per 
patient (KPP) in Sweden), which is a method used for calculating the cost for each  
patient, stay, or visit. The method describes healthcare resource consumption from the 
perspective of diagnosis and is useful for decision-making at all levels of the Swedish 
healthcare sector.  
Data on costs for a follow-up visit to physician for repeat cytology and immediate 
colposcopy with biopsy, respectively, are presented as the average cost per patient from 
three hospitals: Stockholm South General Hospital, Danderyd Hospital, and Karolinska 
University Hospital, Stockholm, Sweden. Wherever necessary, costs were converted 
to the 2008 SEK reference using the consumer price index for Sweden. 
A decision tree based on the Markov model (using TreeAge Healthcare module 
software, 2007) was constructed to evaluate the cost-effectiveness of the three follow-
up strategies described above. Calculations were carried out both considering ASCUS 
and LSIL as one group (ASCUS/LSIL) and separately. These cytological categories 
were considered together in: (1) women of all ages (23-60 years), (2) women in up to 
30 years (<30 years) and (3) women aged 30 years and older (≥30 years). Figure IV:1 
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presents a simplified decision tree for ASCUS/LSIL (23-60 years). Costs (Table 3) for 
the different follow-up strategies represent average cost for the whole population and 
for each cytology and age category separately. For each follow-up strategy, prevalence 
of CIN2+ was used, along with sensitivity and specificity for detection of CIN2+, to 
estimate the number of CIN2+ detected for a simulated cohort of 1000 women in each 
cytology and age group. 
Table IV:1. Prevalence of CIN2+ and HR-HPV and diagnostic performance of follow-up strategies, 
based on results from the clinical trial by Andersson et al.
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Table IV:2. Cost estimates in Swedish kronor (SEK).
Effectiveness is expressed as the number of CIN2+ cases detected by the different 
methods in each simulated cohort. Incremental effectiveness is the difference in number 
of CIN2+ cases detected (by a given follow-up method) per 1000 women in a given 
cytology and age category compared with the next less costly alternative. This report 
analyses the outcome of these different strategies within a time frame of one year and 
includes only the first round of follow-up results of abnormal smears showing ASCUS 
or LSIL. 
The main base case outcome is represented by the incremental cost-effectiveness ratio 
(ICER) per detected CIN2+ case, from the perspective of the Swedish healthcare 
system and includes only direct medical costs. ICER is defined as the additional cost 
per CIN2+ case detected, relative to the next less costly follow-up strategy, where 
ICER= (Cost of Screening strategy A-Cost of screening strategy B)/ (Effect of 
Screening strategy A- Effect of Screening strategy B). The ICER for a strategy is 
computed relative to the next most effective option after eliminating strongly 
dominated strategies (i.e., strategies that are more costly and less effective than other 
options) and weakly dominated strategies that are ruled out by extended dominance (i.e. 
strategies whose costs and benefits are improved by a mixed strategy of two other 
alternatives) (Cantor, 1994). Costs for screening strategies were not discounted since 
the follow-up time is only one year. 
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One way sensitivity analysis was performed by varying the model values to examine 
when HPV triage becomes a cost-effective alternative (Table IV:4, section 5.4.2). Cost 
estimates were varied +100%. Ranges in HPV and CIN2+ prevalence, as well as ranges 
in sensitivity and specificity of the different strategies to detect CIN2+, were derived 
using data from published meta-analyses (Arbyn et al, 2004; Arbyn et al, 2009a; Arbyn
et al, 2005; Arbyn et al, 2006). Among women <30 years and >30 years, prevalence, 
sensitivity, and specificity varied between 0-100%, since data for these parameters 
could not be obtained from the meta-analyses.  
4.6 Statistical analyses 
4.6.1 Paper I 
We developed a multivariate logistic regression model to assess detection rates of 
histologically verified CIN and rates of abnormal cytology findings to compare LBC + 
HPV testing with CC. The model includes the following potential confounders: 
sampling center, age category (<35 years or ≥35 years), and time period (time period 
1=Women screened day 0-224 from study start; time period 2=Women screened day 
225 through December 31, 2006).  Time period was included in the model to adjust for 
the possibility of a learning curve effect in regard to LBC. All explanatory variables 
except sampling center were binary. The interaction of time period x screening method 
was initially included, but since interaction was not significant it was excluded from the 
final analyses. The comparisons between methods are presented as odds ratios (OR) to 
detect CIN and cytological abnormalities, with 95% confidence intervals (95% CI). To 
evaluate the effect of confounding factors on a univariate model, screening method 
alone was used as a predictor to calculate unadjusted OR with 95% CI as well. A 
similar model, including age category and sampling center as potential confounders 
was used for sub-analyses when comparing CIN detection rates among the different 
LBC+ HPV testing screening cohorts (LBC1, LBC2 and LBC3) in relation to the 
control group (CC). 
PPVs for LBC+ HPV testing and for CC in detecting CIN were calculated for all 
positive screening cases as a group (HR-HPV-negative cases of low-grade 
abnormalities were considered WNL), as well as for low-grade cytology and high-
grade cytology separately. Cases for which histological follow-up results were not 
available were excluded from the analysis. To compare LBC+ HPV testing with CC, 
relative risks (RR) for detection were calculated with 95% CI.  
The rate of abnormal cytological findings (both including and excluding HR-HPV-
negative cases of minor cytological abnormalities) and CIN2+ detection rate were 
assessed over time at sampling center A and B, where the LBC+ HPV testing strategy 
was used over an extended period of time (September 2005-December 2007). The 
Jonckheere-Terpstra trend test was used to test significance of changes over time when 
appropriate; otherwise the Pearson χ2 test was used. The null hypothesis of no 
difference was rejected at a significance level of p≤0.05.
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SAS 9.2 (SAS Institute Inc., Cary, NC) was used to perform the logistic regressions, 
LogXact 7.0 (Cytel Inc., Cambridge, MA) was used for the Jonckheere-Terpstra test,  
and StatXact ((Cytel Inc., Cambridge, MA) was used for the Pearson χ2 test. 
4.6.2 Paper II 
Diagnostic performance of HR-HPV detection to identify histopathologically verified 
CIN2+ was assessed by calculating sensitivity, specificity, PPV, and NPV with 95% CI 
(Newcombe, 1998). Proportions were compared using Chi-square statistics (exact 
tests). Means were compared using Student’s t-test. The null hypothesis of no 
difference was rejected at a significance level of p≤0.05.
4.6.3 Paper III 
Data were analyzed using STATISTICA 6.1 software (Statsoft Inc, Tulsa, OK, USA). 
Pearson's χ2 and Yates corrected χ2 (for n<5) tests were used to compare proportions, 
and Student's t-test was used to compare continuous variables between two groups. 
After plotting proportions of HR-HPV- and HPV-infected women and multiple 
infections, respectively, in each age group, a linear or polynomial fit was visually 
assessed to be the best model for logistic regression. We tested whether the 
proportion in each age group decreased linearly with age (log(p/1−p)=b0−b1x) and 
whether this was significantly different from null. Then we added a second degree 
(log(p/1−p)=b0−b1x+b2x2) to test whether the increase in women over a certain age 
was significantly different from null. We controlled for covariation between age and 
age2 using centered age and centered age2 in the model. The larger model, with a 
second degree, provided a better explanation as tested with Nagelkerke R2. Therefore, 
we concluded that the quadratic function, log(p/1−p)=b0−b1x+b2x2, could best 
describe the relationship between (1) prevalence of HR-HPV in LSIL cases and age, 
(2) multiple infections and age, and (3) HR/LR-HPV dominance and age. Logistic 
regressions were also carried out using age group and cytological diagnosis as 
categorical predictors, as well as HPV prevalence as the dependent variable. The null 
hypothesis of no difference was rejected at a significance level of P<0.05. 
4.7 Ethical considerations 
For study I, II, and III ethical permission was obtained from the local ethics committee. 
Informed consent was obtained from all study subjects. Study IV is mainly based on 
results from a previous clinical trial (Andersson et al, 2005c) for which ethical 
permission was obtained, as well as official cost data. Additional permission for cost-
effectiveness analysis is not required. 
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5 RESULTS AND DISCUSSION 
5.1 Paper I: Liquid-based cytology with supplementary HPV 
testing versus conventional cytology 
5.1.1 Distribution of women by age and sampling center 
Table I:1 presents data related to the distribution of women by age and sampling center. 
Age data  CC (n=4261)  LBC+HPV test (n=6075)  
Age range, years  22-60  22-65  
Mean age, years  37.5  37.9  
Median age, years  37  38  
Distribution of sampling centers  CC (n=4261) LBC+HPV test (n=6075) 
A, % (n)  34%  (1457)  24%  (1471)  
B, % (n)  17%  (734)  19%  (1182)  
C, % (n)  15%  (633)  10%  (586)  
D, % (n)  20%  (847)  27%  (1634)  
E, % (n)  9%  (400)  12%  (699)  
F, % (n)  4%  (190)  8%  (503)  
Table I.1. Distribution of women by age and sampling center included in the main analyses.
5.1.2 Main analyses 
Conclusive follow-up histological diagnoses were available for about 80% of all 
women referred for gynecological follow-up, with similar figures found among women 
screened with LBC+HPV testing and CC. Detection rates of histologically verified 
CIN1+, CIN2+, and CIN3+ were similar for both screening strategies (Table I:2). It 
should be noted that adjustment for potential confounders led to a somewhat lower OR 
for CIN detection - to the “disadvantage” of LBC+ HPV testing. The most important 
reason for this was the “time period” variable, which was a significant confounder for 
CIN1+, CIN2+, and CIN3+ detection. Interestingly, both strategies showed higher CIN 
detection rates for women included in time period 2 compared with time period 1. 
During time period 2 a smaller proportion of participants were screened with CC than 
with LBC+ HPV testing. The effect of “age category” was also a significant potential 
confounder. For the CIN2+ endpoint, sampling center was also a significant potential 
confounder. 
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CIN detection rates:  
Method  CIN1+  CIN2+  CIN3+  
CC (%)  2.35% (100/4261)  1.60% (68/4261)  0.99% (42/4261)  
LBC+HPV test (%) 2.30% (140/6075) 1.56% (95/6075)  1.07% (65/6075)  
Comparison of CIN detection rates: LBC+HPV test vs. CC  
Unadjusted OR   
(95% CI)  
0.98 (0.76-1.27)  0.98 (0.72-1.34)  1.09 (0.74-1.61)  
Adjusted OR (95% 
CI)  
0.89 (0.68-1.18)  0.89 (0.64-1.25)  1.02 (0.67-1.54)  
Table I:2. Comparison of CIN detection rates: LBC+ HPV testing versus CC.
The rate of abnormal cytological findings was significantly higher for LBC + HPV 
testing if cases of minor cytological abnormalities among HR-HPV-negative women 
were regarded as abnormal (Table I:3), i.e. reflecting the situation using LBC without 
reflex HPV testing. Time period was a statistically significant potential confounder for 
detection rates of high-grade cytology, since there were increased rates of high-grade 
abnormalities during time period 2 compared with time period 1, for both methods. 
Method  
/Odds ratio  
Abnormal cyt 
incl HR-HPV-neg 
Abnormal cyt 
excl HR-HPV-
neg  
Low-grade 
cytology* 
High-grade 
cytology  
Abnormal cytology report rates:  
CC (%)  3.75% 
(160/4261) 
3.75% 
(160/4261)# 
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1.31% 
 (56/4261) 
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testing (%)  
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Comparisons of rates of abnormal cytology: LBC+HPV test vs. CC  
OR Unadjusted 
(95% CI)  
1.30 (1.07-1.59) 0.90 (0.73-1.11) 0.84 (0.65-1.10) 1.00 (0.71-1.41)  
OR Adjusted  
(95% CI)  
1.32 (1.07-1.63)  0.91 (0.73-1.13) 0.89 (0.67-1.17) 0.94 (0.65-1.35) 
• Cases of low-grade cytology in the LBC group are HR-HPV-pos. # No HPV testing with CC 
Table I:3. Comparison of rate of abnormal cytological findings: LBC+ HPV testing versus CC. 
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CIN detection rates:  
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0.98 (0.76-1.27)  0.98 (0.72-1.34)  1.09 (0.74-1.61)  
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0.89 (0.68-1.18)  0.89 (0.64-1.25)  1.02 (0.67-1.54)  
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The PPVs of the two screening strategies for detection of CIN1+, CIN2+, and CIN3+ 
were similar (Table I:4). When assessing low-grade and high-grade cytology 
separately, PPV of low-grade cytology is higher for LBC+ HPV testing than for CC 
(RR 1.43 (95% CI:0.76-2.67)), whereas in high-grade cytology, PPV for CIN2+ is 
slightly lower for LBC+HPV testing than for CC, with RR 0.91 (95% CI: 0.67-1.22).
Method/Relative risk:  CIN1+  CIN2+  CIN3+  
Overall positive predictive value of abnormal cytology:  
CC, % (n)  79% (100/126)  54% (68/126)  33% (42/126)  
LBC+HPV testing, % 
(n)  
77% (140/182) 52% (95/182)  36% (65/182)  
RR (95% CI)  0.97 (0.86-1.09)  0.97 (0.78-1.20)  1.07 (0.78-1.47)  
Positive predictive value of low-grade cytology:  
CC, % (n)  68% (52/77) 35% (27/77) 16% (12/77)  
LBC+HPV testing, % 
(n)  
69% (74/108) 34% (37/108)  22% (24/108)  
RR (95% CI)  1.01 (0.83-1.24)  0.98 (0.65-1.46)  1.43 (0.76-2.67)  
Positive predictive value of high-grade cytology:  
CC, % (n)  98% (48/49)  84% (41/49) 61% (30/49)  
LBC+HPV testing, % 
(n)  
89% (66/74)  78% (58/74)  55% (41/74)  
RR (95% CI)  0.91 (0.83-1.00)  0.94 (0.79-1.11)  0.91 (0.67-1.22)  
NB: Only cases of abnormal cytology for which histopathological follow-up results were available 
were included in the analyses.  
Table I:4. Comparison of positive predictive values for detection of histologically confirmed CIN: LBC+ 
HPV testing versus CC. 
5.1.3 Sub-analyses 
Table I:5 presents comparisons between the different LBC+HPV testing cohorts and 
CC (described in Material and Methods) for detection of CIN. We found that detection 
of CIN2+ was initially lower with LBC+ HPV testing (LBC1 vs. CC). However, after 
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one year’s experience and more than 4000 screened LBC samples, CIN2+ detection 
rates were higher using LBC+HPV testing compared with CC; the detection rate for 
CIN2+ in the LBC2 cohort was 2.13% versus 1.60% in the CC cohort.  
Although the difference was proportionally large, it was not statistically significant 
(adjusted OR 1.36, 95% CI: 0.92-2.03). When LBC+ HPV testing came into use as a 
routine screening test on a small scale (LBC 3), CIN2+ detection rates were similar to 
CC detection rates in 2005-2006. Age category was a significant potential confounder. 
Parameter  LBC1 vs. CC  LBC2 vs. CC  LBC3 vs. CC*  
Proportion of CIN2+ 
detected using CC  
1.60% (68/4261) 1.60% (68/4261) 1.60% (35/2191)  
Proportion of CIN2+ 
detected using LBC+ HPV 
testing  
1.28% (52/4059)  2.13% (43/2016)  1.57% (53/3383)  
Unadjusted OR for CIN2+ 
detection (95% CI)  
0.80 (0.56-1.15)  1.34 (0.91-1.98)  0.98 (0.64-1.51)  
Adjusted OR for CIN2+ 
detection (95% CI) 
0.86 (0.59-1.24)  1.36 (0.92-2.03) 1.15 (0.73-1.81)  
*Only women screened at the two screening units A and B (as in LBC3) are included in the 
analysis.  
Table I:5.  Screening cohort-specific sub-analyses of CIN2+ detection rates: LBC+ HPV testing versus 
CC. 
When evaluating LBC+ HPV testing over time (at sampling centers A and B), we 
found that the detection rate of CIN2+ increased from 1.1% to about 1.60% during the 
first year, and remained at that level throughout the observed time period (Figure I:1). 
However, this increase is not statistically significant. The rate of abnormal cytological 
findings, including cases of minor cytological abnormalities in HR-HPV-negative 
women, changed significantly over time, with an initial increase followed by a marked 
reduction (Figure I:1). Consequently, the PPV for detection of histologically verified 
CIN2+ increased significantly (Figure I:2). A similar but more stable pattern was seen 
for the rate of abnormal cytological findings excluding cases of minor cytological 
abnormalities among HR-HPV-negative women. 
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Figure I:1. Time trends in LBC+ HPV testing:  rate of abnormal cytological findings and CIN2+ 
detection. Rate of abnormal cytological findings including HR-HPV-negative cases, p=0.01( χ2). Rate of 
abnormal cytological findings excluding HR-HPV-negative cases, p=0.51 (χ2). Proportion CIN2+ 
detected, p=0.26 (Jonckheere-Terpstra trend test, one-sided).   
Figure I:2. Time trends in LBC+ HPV testing: positive predictive values for detection of histologically 
verified CIN2+. Positive predictive value for detection of CIN2+ increased significantly (p=0.005, 
Jonckheere-Terpstra trend test, one-sided). Cases of abnormal cytology without histopathological follow-
up results have been excluded from calculations. 
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5.1.4 Discussion 
This study reflects a dynamic process at a laboratory introducing LBC with 
supplementary HPV testing for screening samples showing ASCUS or LSIL. We noted 
that detection of precancerous lesions improved over time. The sub-analysis showed 
that initially, LBC+ HPV testing detected a smaller rate of histologically verified 
CIN2+ than did CC (Table I:5). In a subsequent cohort, the detection rate of CIN2+ 
was more than 30% higher compared with CC, although the difference was not 
statistically significant. Over the first year the CIN2+ detection rate increased by about 
45% (from 1.1% to 1.6%) for LBC+ HPV testing, although the change was not 
statistically significant (Figure I:1). 
Over time there was also a reduction in the rate of abnormal cytological findings, which 
led to a noteworthy improvement of the PPV for detecting CIN2+ over time, and with 
increasing experience (Figure I:2). These results indicate that with increased experience 
the LBC+ HPV testing strategy may lead to more targeted management of women with 
abnormal screening results. However, in this setting of high-quality, well-established 
conventional cytology screening, no significant differences between the two strategies 
were observed in the main analysis.  
Before the LBC+HPV testing method was introduced on a small scale in routine 
testing, the rate of abnormal cytological findings was instead significantly higher for 
LBC than for CC, a finding made in several previous studies (Beerman et al, 2009; 
Halford et al; Hussein et al, 2005; Hutchinson et al, 1999; Ronco et al, 2007a; Strander
et al, 2007a). A high rate of abnormal cytological findings without a simultaneous 
increase in detection of precancerous lesions would lead to unnecessary resource 
utilization and increase the cost of screening. Moreover, it would reduce the PPV for 
detection of CIN and lead to many unnecessary examinations, causing undue 
psychological and physical stress for women. Therefore we believe that LBC screening 
should be supplemented with high-quality reflex HPV testing.  
Despite incorporation of reflex HPV testing for cases of minor cytological 
abnormalities in the LBC screening arm, our results show that each method is 
associated with a similar PPV for identifying CIN. One possible explanation may be 
that LBC yields both a higher rate of abnormal cytological findings and a higher rate of 
minor abnormalities compared with CC (Beerman et al, 2009; Davey et al, 2007; 
Halford et al; Hussein et al, 2005; Hutchinson et al, 1999; Ronco et al, 2007a; Strander
et al, 2007a). This suggests that reflex HPV testing simply prevents a reduction of the 
PPV for detection of CIN in LBC+ HPV testing compared with CC, at least initially 
while personnel still have limited experience of LBC. 
It should also be noted that this study was carried out in parallel with a study that 
examined HPV triage of minor cytological abnormalities using Hybrid Capture 2 (HC2, 
Digene Inc. Gaithersburg, MD) (Dillner et al) without gold standard verification in 
HC2-negative women. This probably led to a slight overestimate of the PPV of CC for 
detection of CIN, due to a negative selection of women at low risk of current or future 
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CIN (a total of eight cases lost to follow-up due to negative HC2 tests). Such selection 
is already incorporated in the LBC+ HPV testing strategy (two HC2-negative but 
Linear Array HR-HPV-positive cases lost to follow-up). 
The current study shows no clear advantages to the newer screening method LBC + 
HPV testing over CC in detecting CIN, unlike the previous Swedish study by Strander 
et al. The reason for the discrepancy between our results, which stem from a similar 
setting, is unclear. However, both studies share one disadvantage: only women with 
positive screening findings were subjected to gold standard examination with 
colposcopy and biopsy, which introduces verification bias and prevents calculation of 
sensitivity, specificity, and negative predictive value. The reliability of these results 
depends on the assumption that CIN prevalence is equal between the study populations. 
This situation also applies to other studies, and may explain the heterogenous study 
results.  
Moreover, the relative comparison of screening performance depends on the 
performance of the strategy used for comparison (i.e. CC), which differs between sites. 
Incorporating LBC screening with reflex HPV testing in cases of minor cytological 
abnormalities is not likely to have negatively affected detection of CIN2+, since  the 
negative predictive value of HR-HPV detection was extremely high (Froberg et al,
2008).
Other findings are also worth discussing. Performance of LBC+ HPV testing seems to 
somewhat improve identification of the more advanced lesions (CIN3+). This weak 
tendency was also noted for PPVs for CIN. These small differences are far from 
statistically significant. Previous results obtained by others point in the same direction 
(Siebers et al, 2009). Additional studies would be needed to answer the question of 
whether the LBC + HPV testing strategy may improve identification of advanced 
lesions. 
Experience may impact performance when using new methodology in the medical 
field. In this study, personnel at all levels (midwives, cytotechnologists, 
cytopathologists) had extensive experience of conventional cytology screening, while 
everyone had limited experience of LBC at the beginning of this study. One interesting 
finding was that performance improved over time for both screening methods. The 
explanation for this is probably multifactorial. One reason may be the increased focus 
and interest in gynecological cytology generated during this study. Moreover, using 
liquid-based cytology facilitates detection of more subtle changes since cells are better 
preserved, and it is easier to get an overview of the sample slide. It is possible that 
correct interpretation of these subtle changes was initially difficult. Greater vigilance in 
cytological interpretation seems to have influenced the performance for both strategies. 
Previous large randomized controlled trials comparing LBC and CC in population-
based screening found no support for learning curve effects (Ronco et al, 2007a; 
Siebers et al, 2009). An additional study used an expert panel to re-evaluate LBC slides 
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from the Ronco trial in which experience with LBC was initially relatively low 
(Confortini et al), without showing any improved diagnostic performance. However, 
the Siebers evaluation included only 25 false-negative cases.
In late 2006, HPV testing results were taken into account when making the final 
cytological diagnoses. The use of such supplementary virological information may be 
advantageous for the cytopathologist. One finding supporting this hypothesis is the 
marked increase in PPV to detect CIN2+ over time. Another factor that influences 
performance of the screening program is undoubtedly clinical follow-up of abnormal 
results. Over the course of this study, we noted a trend for clinicians to take more 
biopsies, which may have improved detection of CIN over time. Yet another issue to be 
taken into account is that CIN prevalence may fluctuate over time, thereby reducing the 
validity of using historic controls. This should be considered when interpreting sub-
analyses results; changes have occurred over time, and comparisons of women 
screened during different time periods must be interpreted with caution. 
  
In summary, this study shows no significant differences in screening performance 
between the use of liquid-based cytology supplemented with HR-HPV detection and 
conventional cytology. However, the study was conducted over a dynamic time period 
which saw implementation of new methodology, an increased focus on gynecological 
cytology, and improved expertise at all levels in the healthcare chain. We cannot 
exclude that true differences between methods may remain undetected.  
5.2 Paper II: Human papillomavirus reflex testing 
5.2.1 Histological findings 
Table II:1 summarizes cytological findings in relation to histological diagnoses in the 
112 cases of minor cytological abnormalities for which histopathological follow-up 
results were present. 
Table II:1. Liquid-based cytology findings with histological follow-up diagnoses obtained within one 
year of screening in 112 women with minor cytological abnormalities. 
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112 cases of minor cytological abnormalities for which histopathological follow-up 
results were present. 
Table II:1. Liquid-based cytology findings with histological follow-up diagnoses obtained within one 
year of screening in 112 women with minor cytological abnormalities. 
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5.2.2 HPV infection and histological findings 
In all, 81% of all samples were HPV-positive. There was a significant proportion of 
multiple infections and overlap of infections with HPV types from one, two, or all three 
risk categories (HR-, pHR- and LR-HPV). The prevalence of HPV-infected samples 
increased with increasing degree of CIN (p=0.026). Sixty-three percent of the samples 
were HR-HPV-positive (Table I:2). In this cytologically selected material, the NPV for 
the LA HPV test to detect CIN2+ lesions was 100% ( 95% CI: 90-100%). As shown in 
Figure II.1, all 15 cases of CIN2+ were HR-HPV-positive, compared with 56% (22/39) 
of the CIN1 and 57% (33/58) of the WNL cases (p=0.019).  
Figure II:1. Prevalence of HPV risk categories related to histological diagnosis in 112 cases of minor 
cytological abnormalities. Since infection by HPV types of different risk categories can overlap, the sum 
of the HR-, pHR- and LR-HPV prevalences in each histological diagnosis group can exceed 100%. 
Figure II:2. Prevalence of HPV hierarchic risk categories related to histological diagnosis in 112 cases 
of minor cytological abnormalities.  
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5.2.3 Distribution of HPV genotypes and histological findings 
To detect all cases of CIN2+, the assay had to accurately detect at least HPV types 16, 
18, 31, 52, and 58. HPV 45 was detected as frequently as HPV 52 and 58 among the 
CIN2+ cases (13% or 2/15), but never as a single HR-HPV infection. In this limited 
material, we were able to demonstrate a significant correlation between HPV types 16 
(p=0.0045), 18 (p=0.039), and 31 (p=0.006) with high-grade cervical lesions. Presence 
of co-infection with other HPV types has not been taken into consideration when 
performing the calculations (Figure II:3). 
Figure II:3. Relative distribution of HR-, pHR- and LR-HPV genotypes in liquid-based cytology samples 
showing minor cytological abnormalities, related to histological diagnosis: WNL (n=58) (light grey 
bars), CIN1 (n=39) (dark grey bars) and CIN2+ (n=15) (black bars).  
Among patients with minor abnormalities in their screening smears and subsequent 
histological findings showing CIN2+, HPV types 16, 31 and 18 clearly stand out as the 
most common, present in single or multiple infections in 40% (6/15), 33% (5/15), and 
27% (4/15) of  cases, respectively. Altogether, they were present in 73% (11/15) of the 
samples. Out of the 15 CIN2+ cases, 53% (8/15) were infected with HPV 16 and/or 
HPV 18; however, only three of these women were not infected with additional HPV 
types.
5.2.4 Multiple infections  
In all, 54% had multiple HPV infections, and of 91 HPV-infected individuals, 67% 
were infected by more than one HPV type. Multiple HPV infection was slightly more 
common in cases of histological CIN2+ than in CIN1 and WNL cases (73, 64, and 
67%, respectively). Among the HR-HPV-positive samples, 41% (29/70) were infected 
by more than one HR-HPV type. Among HR-HPV-positives, multiple HR-HPV 
infections were slightly more common in CIN2+ (Figure II:4) than in CIN1 and WNL 
cases. These weak trends may reflect that multiple HPV infection increases the 
probability of harboring a highly oncogenic HPV type. 
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Figure II:4. Prevalence of single vs. multiple HR-HPV infections in HR-HPV-positive cases related to 
histological diagnosis. 
5.2.5 Discussion 
Reporting rates in the Scandinavian screening programs differ from those in the Anglo-
Saxon world. Scandinavian cytologists tend to rate the samples as "within normal 
limits" more frequently than British or American cytologists (abnormal smear rate: 3-
5% vs. 10-15%), discounting subtle changes in deference to achieving cytological 
certainty (Scott R et al, 2002). In spite of these differences, our results suggest that the 
value of HR-HPV detection in cases of minor cytological abnormalities is high even in 
a Swedish context. 
Among cases of minor cytological abnormalities detected using LBC, HR-HPV 
detection using LA has a 100% (95% CI: 90-100%) negative predictive value for high-
grade cervical dysplasia during a maximum follow-up time of 1 year (Table II:2). This 
is similar to findings in a large-scale prospective study including cases of ASCUS 
where carcinogenic HPV detection using the same HPV test showed an excellent NPV 
(95.67%; 95% CI: 94.22-96.85%) for 2-year cumulative CIN2+ (Castle et al, 2008). In 
the present study we used a different definition for carcinogenic or high-risk HPV, 
classifying HPV 66 and 68 as pHR-HPV types, which probably only has a marginal 
effect on performance of the HPV test. Our results suggest that the pHR-HPV group is 
of little or no importance in a screening context according to the IARC classification of 
HPV types by carcinogenicity (Bouvard et al, 2009).
In the LSIL group, HR-HPV prevalence is high, about 80-85%, among women younger 
than 30 years, and drops to about 50% among women aged 30 years or older. For this 
reason, specificity of the HPV detection test can be improved by setting an age limit of 
30 years for HPV "reflex" testing in cases of LSIL. An age-limit at 35 years in cases of 
LSIL has been suggested (Ronco et al, 2007), yielding a somewhat higher specificity 
for histologically confirmed CIN2+ (using Hybrid Capture 2 for HPV detection), 
compared with our findings for women aged 30-59 years. In cases of ASCUS, where 
HR-HPV prevalence is considerably lower (Brismar-Wendel et al, 2009), the HR-HPV 
59
Figure II:4. Prevalence of single vs. multiple HR-HPV infections in HR-HPV-positive cases related to 
histological diagnosis. 
5.2.5 Discussion 
Reporting rates in the Scandinavian screening programs differ from those in the Anglo-
Saxon world. Scandinavian cytologists tend to rate the samples as "within normal 
limits" more frequently than British or American cytologists (abnormal smear rate: 3-
5% vs. 10-15%), discounting subtle changes in deference to achieving cytological 
certainty (Scott R et al, 2002). In spite of these differences, our results suggest that the 
value of HR-HPV detection in cases of minor cytological abnormalities is high even in 
a Swedish context. 
Among cases of minor cytological abnormalities detected using LBC, HR-HPV 
detection using LA has a 100% (95% CI: 90-100%) negative predictive value for high-
grade cervical dysplasia during a maximum follow-up time of 1 year (Table II:2). This 
is similar to findings in a large-scale prospective study including cases of ASCUS 
where carcinogenic HPV detection using the same HPV test showed an excellent NPV 
(95.67%; 95% CI: 94.22-96.85%) for 2-year cumulative CIN2+ (Castle et al, 2008). In 
the present study we used a different definition for carcinogenic or high-risk HPV, 
classifying HPV 66 and 68 as pHR-HPV types, which probably only has a marginal 
effect on performance of the HPV test. Our results suggest that the pHR-HPV group is 
of little or no importance in a screening context according to the IARC classification of 
HPV types by carcinogenicity (Bouvard et al, 2009).
In the LSIL group, HR-HPV prevalence is high, about 80-85%, among women younger 
than 30 years, and drops to about 50% among women aged 30 years or older. For this 
reason, specificity of the HPV detection test can be improved by setting an age limit of 
30 years for HPV "reflex" testing in cases of LSIL. An age-limit at 35 years in cases of 
LSIL has been suggested (Ronco et al, 2007), yielding a somewhat higher specificity 
for histologically confirmed CIN2+ (using Hybrid Capture 2 for HPV detection), 
compared with our findings for women aged 30-59 years. In cases of ASCUS, where 
HR-HPV prevalence is considerably lower (Brismar-Wendel et al, 2009), the HR-HPV 
60
prevalence was not significantly higher among women under the age of 30 years than 
among older women, for which reason the diagnostic value of HPV testing in this 
group is independent of age.  
However, in a recent study on HPV triage against the background of conventional 
cytology (CC) screening, HR-HPV prevalence was high even among young women 
with ASCUS (Dillner et al). This difference may be attributable to differences in 
cytological evaluation between LBC and CC. In the study by Dillner et al, Hybrid 
Capture 2 was used for HPV triage, whereas we used the LA HPV detection and 
genotyping method. Since LA is a more sensitive assay than HC2, our use of a different 
test is not likely to explain this difference among younger women.   
In this study, the HPV triage model using the LA HPV test for all cases of ASCUS and 
for cases of LSIL in women ≥30 years, could reduce the need for extensive follow-up 
investigations by about 50%, while retaining good patient safety. In such cases, 
cytological evaluation and virological analysis could be performed on the same 
material ("reflex testing"). Because there is only one sampling event, sampling error 
would be reduced. Screening program costs would also be reduced, because both 
analyses can be performed without recalling the patient. The decision of whether to set 
an age-limit for HPV "reflex" testing in LSIL cases should be based on health-
economic calculations. 
According to our results, only the HR-HPV group had a statistically significant 
correlation with CIN2+, for which HR-HPV types 16, 18 and 31 were the most 
important. In this small material, in order to identify all cases of high-grade cervical 
lesions, the HPV test had to accurately detect HPV 16, 18, 31, 52, and 58. These HPV 
types are represented among the main worldwide oncogenic HPV types (HPV 16, 18, 
31, 33, 35, 45, 52, and 58), which account for about 91% of all cervical cancer cases 
worldwide (de Sanjose et al; Smith et al, 2007). However, since a high negative 
predictive value is necessary in a "reflex" screening situation, all HR-HPV types need 
to be accurately detected.  
The main value of introducing LBC combined with HPV “reflex” testing is probably an 
improved ability to identify women with an increased risk of developing pre-malignant 
and malignant cervical lesions, without increasing the abnormal cytology reporting rate. 
Unnecessary investigations and unnecessary psychological stress could be avoided, and 
resources could be used for more accurately directed follow-up of women with 
abnormal cytological findings.  
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5.3 Paper III: Age-specific prevalence of HPV genotypes in ASCUS 
and LSIL 
5.3.1 HPV prevalence 
In all, 82% were positive for one or more of the 37 included HPV types. HPV 
prevalence ranged from 92% in the 20-29 year age group to 62% in women aged 40-45 
years. Prevalence was 67% in women over 50 years. Age-specific prevalence for HPV 
(37 types) and HR-HPV (12 or 13 types) was higher in younger age groups and there 
was a linear decline with age (p<0.001, Table III.1). HPV was more common in women 
with LSIL than with ASCUS (93% vs. 63%, p<0.001).  HPV prevalence was 
significantly dependent on age group (Figure III:1). However, there is an apparent 
tendency for increasing discrepancy with lower, and especially higher age.  
HR-HPV (12 types) was found in 71% of all women with LSIL and 49% of women 
with ASCUS (p=0.001). These figures were only minimally influenced if HPV 68 was 
considered to belong in the HR-HPV group. Figure 1 shows that HR-HPV prevalence 
was age-dependent in women with LSIL, decreasing with age until the age of 50 years 
(p=0.19 for age2), after which a small, statistically insignificant increase was found. In 
ASCUS cases, a linear correlation between HR-HPV and age was found. A statistically 
significant age-specific difference in HR-HPV between ASCUS and LSIL cases was 
only seen in the youngest women, aged 20-24 years (Table III:1) 
Figure III:1. Age-specific prevalence of human papillomavirus (HPV) (all types) and HR-HPV 
infection in women with ASCUS and LSIL. Human papillomavirus all types P(age group × cytological 
diagnosis)=0.10; LSIL P(age)=0.20, P(age group)=0.03, P(age2)=0.003; ASCUS P(age)=0.001, 
P(age group)=0.04, P(age2)=0.34; HR-HPV P(age group × cytological diagnosis)=0.15; LSIL 
P(age)=0.001, P(age group)=0.01, P(age2)=0.19; ASCUS P(age)=0.04, P(age group)=0.11, 
P(age2)=0.16; all P-values calculated by logistic regression.
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5.3.2 HPV genotype distribution 
Figure III:2 shows the prevalence of HR-HPV genotypes (including pHR-HPV 68) in 
each age group in all women. HPV 16 was the most common HR-HPV type and was 
found in 23% of the HPV-positive women, ranging from 30% (20/67) in women aged 
20-29 years to 14% (3/22) in women aged 45-49 years (p=0.22). HPV 18 was found in 
only 10% of all HPV-positive women. HPV 51 was equally or more common than 
HPV 16 in women over 45 years of age. Among women with ASCUS, the most 
prevalent HR-HPV type was HPV 16 (16%), followed by HPV 51 and 52 (10%). 
Among women with LSIL, HPV 16 was found in 21%, followed by HPV 56 (11%).  
Figure III:2.  Age-specific distribution of the HR-HPV types including pHR-HPV 68. The total exceeds 
100% since many women are infected with more than one HR-HPV genotype.
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Table III:2 outlines women infected with HPV 16, 18, clade 9 HPV types, and clade 7 
HPV types to elucidate the preventive potential of current prophylactic HPV vaccines 
against minor cytological abnormalities. As shown in Figure III.4, we found a shift in 
predominant HPV genotypes with age. The proportion of LR-HPV types increased with 
age, following a quadratic function (p=0.001).
Figure III:4. Age-dependent shift in LR vs pHR+HR frequency (% of all HPV infections). LR and 
pHR+HR P(age2)<0.001 (logistic regression). LR=low-risk HPV, pHR=probable high-risk HPV, and 
HR=high-risk HPV.
Table III:2. Preventive potential of current HPV vaccines, ASCUS and LSIL.
5.3.3 Multiple infections 
Multiple infections were common (Figure III:5). On average, there were 2.5 genotypes 
per HPV-positive sample. In one LSIL sample, nine different genotypes were found. In 
all, 54% (185/343) of all women carried more than one HPV type. Taking only HPV-
positive samples into account, multiple infections were equally common in ASCUS and 
LSIL (65% and 66% respectively). The age-specific prevalence of multiple infections 
followed a quadratic function in LSIL cases (p=0.001, Figure III:5). 
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Figure III:5. Age-specific prevalence of multiple infections. Multiple HPV P(age group)=0.08, 
P(cytological diagnosis)=0.63, P(age group × cytological diagnosis)=0.73, LSIL P(age2)=0.001, 
turning point 41.6 years, ASCUS P(age2)=0.76. Multiple HR-HPV P(age group)=0.04, P(cytological 
diagnosis)=0.71, P(age group × cytological diagnosis)=0.24, LSIL P(age2)=0.04, turning point 38.6 
years, ASCUS P(age group)=0.27, P(age2)=0.34. All P-values calculated by logistic regression. 
A similar pattern was seen for multiple HR-HPV infections among the HR-HPV-
positive LSIL cases (p =0.04). Among HR-HPV-positive samples, 39% (85/217) were 
infected by more than one HR-HPV type, and similar results were found for ASCUS 
and LSIL. 
In all, there were 710 individual infections. Co-infection was equally common among 
LR-HPV genotypes (92%, 243 out of 268) and pHR-HPV genotypes (91%, 87/101). 
Individuals infected with HR-HPV were somewhat less likely to be infected with a 
second HPV type (83%, 283/341, p=0.06). The HR-HPV types that were most 
commonly seen in co-infection with HPV 16 (clade/species 9) were HPV 59 (46%), 45 
(38%), and 39 (28%), belonging to HPV clade/species 7. Interestingly, HPV 18 did not 
occur with either HPV 39 or HPV 45 (p≤0.01). The high-risk types most commonly 
seen in co-infection with HPV 18 were HPV 56 (17%), 33(14%), and 51 (14%), which 
did not differ from frequencies of HPV 16 infection. HPV 16 infected women were 
more often co-infected with clade 7 HPV types than with similar clade 9 types 
(p=0.06). HPV 18-infected women carried genotypes from clade 9 in 43% of cases, 
compared with similar clade 7 genotypes in 11% (p=0.02).
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second HPV type (83%, 283/341, p=0.06). The HR-HPV types that were most 
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5.3.4 Discussion 
We found that HPV prevalence in women with screening results showing minor 
cytological abnormalities varied with age and there was a slight but non-significant 
increase in HPV prevalence in women over 45 years. Others have found similar age-
related patterns and attributed this slight increase to menopausal hormonal and 
immunological changes that may facilitate HPV DNA detection or reactivate latent 
infections from exposures earlier in life (reviewed by (Bosch et al, 2008)). Such 
findings may also be related to sexual behavior and thus to increased exposure, as 
many women in this age group have divorced and remarried (Stevenson and Wolfers, 
2007). Our finding of an increasing proportion of low-risk types in post-menopausal 
women was also observed by (Castle et al, 2006). This observation, including the 
increase in multiple infections among women over 50 years, might also reflect 
changes in hormonal or immunological status occurring at menopause. Some 
evidence suggests a hormonal effect on oncogene expression, at least for HPV16 and 
18, through action on progesterone/glucocorticoid-responsive elements in the long 
control region of the HPV genome (Cole & Danos, 1987; Gloss et al, 1989).
However, more recent research has called such a mechanism into question (Ruutu et 
al, 2006), and would instead suggest hormonal effects impairing apoptosis of infected 
cells. Oral contraceptives and high parity are known risk factors for cervical cancer 
(Munoz et al, 2002). One common characteristic of these factors and menopause is a 
state of anovulation. To our knowledge, no studies have explored whether other 
ovulatory hormones such as gonadotropins, inhibin, or prostaglandins could influence 
HPV-induced carcinogenesis.
The average prevalence of HR-HPV was higher in LSIL (71%) than in ASCUS cases 
(49%), which is consistent with a previous meta-analysis (Arbyn et al, 2009a). 
However, the LSIL cases had a significantly lower rate of HR-HPV than the rate 
reported by the ASCUS-LSIL-Triage-Study (ALTS) Group (82.9%) (2000). The 
ALTS group concluded that triage HPV testing of LSIL had limited potential for 
clinical decision making. The difference in HR-HPV prevalence might be due to 
different criteria for defining ASCUS and LSIL, and also to a difference in the mean 
age of the populations (24.9 years in ALTS and 33.6 years in this study). We used the 
LA assay covering 37 HPV types and defined 12 HPV types as high risk. ALTS used 
Hybrid Capture II to define the same 12 HR-HPV types and HPV68 as high risk. This 
approach should not introduce any major difference, as HPV68 without co-infection 
with another HR-HPV was found only in one case of ASCUS and in one case of 
LSIL in our material.  
Age-dependent HPV prevalence in women without cytological abnormalities is a 
known phenomenon (Bosch et al, 2008; Castle et al, 2006; de Sanjose et al, 2007).
Age-dependent prevalence in LSIL has been observed and discussed by Ronco et al,
(Ronco et al, 2007b), although they only compared women who were older or 
younger than 35 years. High-risk human papillomavirus prevalence was age-
dependent in our LSIL cases, but more stable in ASCUS cases. When using 5-year 
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intervals for age grouping, the only significant difference in HR-HPV prevalence 
between ASCUS and LSIL was found within the youngest (20–24 years) age group. 
In LSIL, the largest drop in HR-HPV prevalence was after the age of 30 years (83% 
in women <30 vs. 60% in women ≥30, P<0.001). These findings suggest that age 30, 
or even younger, is a suitable cut-off point for HR-HPV triage in LSIL, when 
consideration is given only to the prevalence argument. This is supported by the 
results from Paper II in which 48% of women over 30 years with LSIL and 60% of 
women with ASCUS were HR-HPV-negative and none of them had a histology result 
of CIN2+ (Froberg et al, 2008) and could therefore have avoided additional 
investigation.  
One of the most noteworthy findings in our study was the high frequency of multiple 
infections. Similar results were previously reported by (Cuschieri et al, 2004) in a 
general screening population from Edinburgh using a linear array assay capable of 
identifying 27 types and similar liquid-based sampling. We found that the prevalence 
of multiple infections was consistent with a quadratic function, with increasing 
prevalence among women over the age of 50 years. One may speculate whether this 
finding is caused by re-infection, triggering of a latent infection, or if detection is 
favored by menopausal changes in the epithelium as mentioned above. 
The observed elevated specific co-infection rates of HPV16 with certain other HPV 
types, such as HPV39, 45, and 59, may be because of differences in susceptibility to 
certain genotypes (all clade/species 7), as postulated by Liaw (Liaw et al, 2001). An 
international epidemiological study based on the IARC HPV prevalence surveys 
including > 13 000 individuals noted a tendency for clustering of HPV types with a 
high degree of similarity in the L1 region with high expected-to-observed ratios for 
closely homologous types, including HPV33/58, 18/45, 33/35, and 31/35 (Vaccarella
et al). We found that HPV18-infected women were more likely to be co-infected with 
non-related clade/species 9 types than with similar clade/species 7 types, arguing 
against specific susceptibility. This may be a random finding, or an artifact caused by 
the relatively large contribution of HPV 16 and 18 among the species 9 and 7 HPV 
types detected. 
Since 26% of all women were positive for HPV16 and/or 18 (Table II:2), and 60% 
were positive for any of the species 7 or 9 HPV types, one might estimate that HPV 
vaccination will decrease rates of low-grade abnormalities by about 26-60%. 
Although this estimation is uncertain due to the frequent multiple infections, it is 
similar to the estimation obtained from epidemiological studies by the IARC; in 
ASCUS 6-27% were positive for HPV 16 and/or 18 and the corresponding figure for 
LSIL was 16-32% (Clifford et al, 2006).  
As many as about 75% of all these women could benefit from catch-up vaccination, 
provided full cross-protection can be assumed, as discussed by Castellsague 
(Castellsague et al, 2008). Our results show relative frequencies of individual HR-
HPV types similar to those found during primary screening in a Swedish multicenter 
study comprising 5696 women aged 32–38 years (Swedescreen) (Naucler et al,
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2007c). The Swedescreen group found that HPV16, 31, and 33 represented the 
highest population-attributable risk proportion in the development of CIN2+. Human 
papillomavirus type 18 was only the sixth most commonly identified HR-HPV type 
resulting in CIN2+.  
Worldwide, HPV33 is associated with the third highest odds ratio (OR 373.5) for 
squamous-cell cervical cancer, behind HPV16 (OR 434.5) and HPV59 (OR 419.5) 
(Munoz et al, 2003). Considering that odds ratios vary for different HPV types, 
genotyping is needed to estimate risk in the individual case as well as to plan clinical 
follow-up and vaccination strategy. We think our data support the statement of 
Cuschieri et al (2004) that a broad spectrum test should be implemented until the true 
impact of the persistence of less common HR-HPV types in neoplastic progression is 
established. 
5.4 Paper IV: Economic analysis of HPV triage 
5.4.1 Cost-effectiveness of HPV triage 
For ASCUS ≥30 years (Table IV:3), HPV triage is the least costly alternative, while 
Cytology is dominated by Colposcopy with biopsy. Colposcopy with biopsy detects 88 
more CIN2+ lesions per 1000 women and is a cost-effective alternative with an ICER 
of SEK 2 056 per additional CIN2+ case detected, compared with HPV triage, 
assuming that society is willing to pay the additional cost. However, for all cytology 
and age categories except ASCUS ≥30 years, both HPV triage and Cytology are 
strongly dominated by Colposcopy with biopsy, i.e. Colposcopy with biopsy constitutes 
the least costly and most effective follow-up strategy.  
For women older than 30 years, HPV triage is less costly and equally or more effective 
than Cytology as a follow-up strategy for ASCUS and LSIL (considered together and 
separately). In the categories which include women younger than 30 years, HPV triage 
is the most costly follow-up strategy, except for ASCUS 23-60 years, where HPV 
triage is SEK 124 less costly (SEK 2 662 vs. SEK 2 538) and equally effective 
compared with Cytology. For ASCUS/LSIL 23-60 years, HPV triage is more effective 
than Cytology, detecting 45 more CIN2+ cases per 1000 women, at a marginally higher 
cost of SEK 129 (SEK 3 057 vs. SEK 2928). 
Comparing HPV triage to Colposcopy with biopsy, we found that for ASCUS/LSIL 23-
60 years (Table 3), HPV triage is SEK 625 more costly (SEK 3 057 vs. SEK 2 432), 
while less effective, detecting 40 fewer CIN2+ cases per 1000 women. The largest 
difference in cost between these two strategies was seen for LSIL <30 years, where 
HPV triage was SEK 1 098 more costly (SEK 3 530 vs. SEK 2 432) and less effective, 
detecting 17 fewer cases of CIN2+ per 1000 women. The smallest difference in cost 
between the same strategies was seen for ASCUS 23-60 years, where HPV triage is 
SEK 106 more costly than Colposcopy with biopsy (SEK 2 538 vs. SEK 2 432) , 
detecting 77 fewer CIN2+ cases per 1000 women.  
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5.4.2 Sensitivity analysis 
When changing costs for follow-up strategies, the model results were most sensitive to 
change in HPV test costs (Table IV:4). Most importantly, considering ASCUS and 
LSIL as one group, HPV triage is the least costly and next most effective follow-up 
strategy when HPV test cost is below SEK 231 for women 23-60 years and below SEK 
522 for women ≥30 years, while Cytology is a dominated alternative. For ASCUS, 
management with HPV triage is the least costly alternative when the HPV test cost is 
below SEK 749 for women 23-60 years, and below SEK 1 035 for women  ≥30 years. 
For ASCUS <30 years, HPV triage is no longer a dominated alternative if HPV test 
cost is below SEK 200. For LSIL ≥30 years, HPV triage is no longer a dominated 
alternative if HPV test cost is below SEK 252 for women. 
Moreover, in ASCUS/LSIL and ASCUS, the model results were sensitive to changes in 
costs for visit to midwife and physician, as well as changes in costs for visit to 
physician for colposcopy with biopsy (Table IV:4, see the following page). 
5.4.3 Discussion 
A high sensitivity and negative predictive value to detect high-grade cervical lesions 
are required for HPV triage to be considered an attractive alternative for follow-up of 
ASCUS and LSIL. It should be noted that in the clinical trial upon which this analysis 
is based (Andersson et al, 2005a), the performance of HPV triage was low compared 
with other studies on the same topic (Arbyn et al, 2006; Cuzick et al, 2008).
This cost-effectiveness analysis shows that an additional 85 CIN2+ cases would be 
detected per 1000 women with ASCUS or LSIL going through secondary screening per 
year, if immediate colposcopy with biopsy were offered to all these women, instead of 
repeat cytology. Using the CIN2+ cases detected in this study, the exclusive use of 
immediate colposcopy with biopsy for secondary screening in Sweden translates into 
1822 additional CIN2+ cases detected, compared with exclusive use of repeat cytology. 
Compared with HPV triage, immediate colposcopy with biopsy would detect 858 
additional CIN2+ cases. The choice of alternative follow-up strategy is of great 
importance since an estimated 5-30% of missed CIN2+ cases could progress to 
invasive cancer (McCredie et al, 2008; Ostor, 1993). 
According to the results from our study, HPV triage is the least costly follow-up 
strategy for ASCUS ≥30 years compared with immediate colposcopy with biopsy and 
repeat cytology, although it is less effective than immediate colposcopy with biopsy.  In 
the sensitivity analysis, the model results were most sensitive to changes in HPV test 
costs. Lower costs for HPV testing are needed in order for HPV triage to be a cost-
effective follow-up strategy compared with immediate colposcopy with biopsy for 
women <30 years with LSIL. Additional support for this idea was presented in a British 
cost-effectiveness study showing that HPV triage would be cost-neutral at a price of 
£34.37, and cost-saving below that level, compared with colposcopy (Guyot et al,
2003).
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In today’s cost situation however, HPV triage is dominated by immediate colposcopy 
and biopsy in all groups except ASCUS ≥30 years, and immediate colposcopy with 
biopsy provides a cost-effective alternative for follow-up of minor cytological 
abnormalities in all age groups. In the present analysis, changing the age limit for HPV 
triage from 30 to 35 years (data not shown) does not change this conclusion. 
Compared with repeat cytology, HPV triage is a less costly and equally or more 
effective follow-up alternative for women ≥30 years. Repeat cytology is the overall 
least effective follow-up method and a dominated strategy for follow-up of ASCUS and 
LSIL in all age groups. Our results indicate that HPV triage is a preferred option to 
repeat cytology for follow-up of minor cytological abnormalities among women ≥30 
years. 
If liquid-based cytology were used in primary screening, HPV triage would become 
substantially less expensive since leftover sample after cytology slide preparation could 
easily be used for HPV testing (so-called HPV “reflex” testing), thereby avoiding costs 
for an additional physician visit. It is noteworthy that performance between liquid-
based and conventional cytology may differ, which may influence cost-effectiveness of 
follow-up methods. 
Use of an age-limit for HPV triage has previously been discussed. In the current study, 
all HR-HPV-positive women were referred for colposcopy with biopsy. The ASCUS-
LSIL Triage Study (ALTS) investigated whether restricting HPV triage to women ≥29 
years would also enable effective HPV triage in cases of LSIL. Results showed that 
although HPV test positivity rate was somewhat reduced in the older age group (74% 
vs. 88% in women aged 23-28 years), sensitivity of HPV triage for detection of CIN3 
was also reduced (83% in the older vs. 98% in the younger age group), which is why 
HPV triage was not considered to be effective for women with LSIL regardless of age. 
For ASCUS, a small reduction in HPV test sensitivity for detection of CIN3+ with 
higher age was seen (Sherman et al, 2002). These figures are similar to those found in 
the clinical trial by Andersson et al upon which this cost-effectiveness analysis is based 
(Andersson et al, 2005a; Ostensson et al). In the HPV triage trial by Ronco et al (Ronco 
et al, 2007b), performance of Hybrid Capture 2 was also high in women >35 years. In 
contrast to previous studies, HPV test performance was low for triage of ASCUS, with 
somewhat better sensitivity for detection of CIN2+ in the younger age group. This 
phenomenon may be related to the sensitivity of the HPV detection method used and/or 
sampling technique. 
The cost-effectiveness analysis is based on a split sample trial where HPV tests were 
evaluated in a routine clinical setting, and HPV test results were evaluated in a blinded 
fashion in regard to follow-up cytological and histological diagnoses. The strength of 
this approach is that it minimizes observer bias and confounding from other variables 
that may affect the results. Some limitations should however be pointed out. The 177 
patients in the clinical trial represent a limited number of patients and the results should 
therefore be interpreted with caution. The follow-up time in the clinical study is limited 
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to only one year, which implies that costs and health outcomes after the cessation of the 
clinical study is not available. To improve decision-making on societal efficiency of 
healthcare resource allocation, economic evaluations should ideally be based on a societal 
perspective. This also implies inclusion of costs outside the healthcare sector (e.g. 
indirect costs). Ideally quality adjusted life years (QALYs) should also be used as the 
outcome measure.  
Today, significant costs are associated with the unnecessary follow-up of women with 
minor risk of developing cervical cancer (Naucler et al, 2007c). Since a majority of 
women with ASCUS or LSIL have normal findings or low-grade lesions with a high 
rate of spontaneous resolution, the use of HPV triage could be considered a less 
aggressive follow-up strategy. Development of high-throughput HPV DNA detection 
of high quality is rapid. Efficient triage, using highly sensitive HPV DNA testing at 
lower cost, would reduce the financial burden as well as the negative psychological and 
physical effects associated with abnormal screening results and colposcopic 
examination. 
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
Paper I:
When comparing LBC with supplementary HPV testing with conventional cytology in 
population-based screening, we could not demonstrate any significant differences in 
relative sensitivity for detection of CIN2+ or CIN3+, or any improvement in PPV for 
such lesions. However, it is noteworthy that the performance of both methods improved 
significantly over time, indicating that dynamic changes occurred during the study 
period, leading to improved cytological evaluation. The introduction of LBC may have 
resulted in enhanced detection of subtle cellular changes and an increased vigilance in 
cytological interpretation. 
The sub-analyses showed that during the first fifteen months, total rate of abnormal 
cytological findings increased due to a high proportion of minor abnormalities, and 
detection of CIN2+ also gradually increased. When LBC sampling continued in small-
scale routine during 2007, abnormal cytology report rates decreased significantly, to a 
level below that usually seen for CC. Although CIN2+ detection rates remained high, 
the decreased rate of low-grade cytology suggests a shift from overdiagnosis to 
overconfidence. The detection of high-grade precancerous lesions could be improved 
by a lower threshold to test for HR-HPV when nonspecific subtle cytological changes 
are encountered. This is in fact the value of HPV reflex testing – it allows for 
uncertainty and humility when confirming a preliminary diagnosis of ASCUS or LSIL. 
Monitoring the rate of abnormal cytology is highly important for maintaining a 
reasonable level of cytological evaluation. 
To determine whether one of these screening strategies is superior to the other in the 
Swedish healthcare arena, additional evaluations need to be conducted in a setting 
where the staff is highly experienced in using both methods, and using a study design 
that includes gold standard verification of all cases. A prospective evaluation covering a 
second screening cycle is needed to answer whether either of these methods is superior 
when it comes to lowering the rate of CIN3+ (Arbyn et al). Improved knowledge about 
possible differences in performance between these two methods will also be important 
if future screening should change to include primary HPV testing, since adjunct 
cytology testing is likely to be needed. 
Paper II, and III:  
The NPV of HR-HPV detection for histologically confirmed high-grade lesions in 
cases of minor cytologicalabnormalities was 100%. An age limit for HPV reflex testing 
may be motivated in cases of LSIL. By using HPV "reflex" testing, additional extensive 
workup can safely be avoided in about 50% of all cases of ASCUS and LSIL among 
women ≥30 years. The prevalence of HR-HPV is similar among women with ASCUS 
and LSIL after the age of 30 years, supporting an age limit of 30 years for triage testing 
in LSIL cases and no age limit in ASCUS cases. Such a strategy can improve the 
effectiveness of the screening program, and reduce risks of overdiagnosis and 
overtreatment.  
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HPV triage/reflex testing may also lead to an improved protective effect by improving 
follow-up of HR-HPV-positive women. In cases where histology findings were WNL 
or CIN1, more than 50% were HR-HPV-positive. These women need to be followed-
up, given their elevated risk for developing a high-grade cervical lesion. Repeated HPV 
genotyping allows for diagnosis of persistent HPV infection and for risk stratification 
of women with cytological abnormalities, which might be useful in clinical 
management (Naucler et al, 2007; Wheeler et al, 2006; Bulkmans et al, 2007). 
Our results from Paper I showed that LBC yielded a higher rate of minor cytological 
abnormalities initially, which might explain the lower prevalence of HR-HPV in young 
women with screening results showing ASCUS, compared with other recent Swedish 
data in a conventional cytology screening setting (Dillner et al). At the same time, our 
data are consistent with many previous HPV triage trials, showing that HPV triage is 
worthwhile in ASCUS irrespective of age. 
Paper III showed that multiple infections and LR/HR-HPV dominance are age-
dependent. Genotyping in longitudinal design is needed to elucidate the importance of 
multiple infections in cancer progression and in cross-protection from vaccination. 
There is evidence that HPV types 16, 18, and 45 in particular are linked to high 
carcinogenicity, since they seem to lead to cancer at least 5 years earlier than do other 
HR-HV types (de Sanjose et al). Infections with these HPV types demand special 
consideration in follow-up and treatment of women with abnormal screening results.  
Paper IV:
HPV tests used in HPV triage/reflex testing require high sensitivity and NPV for 
detection of CIN2+ and in particular CIN3+; otherwise they would reduce sensitivity of 
screening. HPV triage was the least costly alternative among women with ASCUS > 30 
years, although less effective than immediate colposcopy with biopsy. In the current 
setting of conventional cytology screening, HPV triage is not cost-effective, whereas 
immediate colposcopy with biopsy is the cost-effective alternative. HPV triage could 
potentially become a cost-effective management option, if HPV testing were performed 
as a “reflex” test, thereby avoiding an extra medical visit and bringing costs down 
below the cut-off, and if costs for HPV tests were lower. Our results motivate a 
discussion about what requirements should be fulfilled by HPV tests which are used for 
triage of ASCUS and LSIL, from a patient safety and cost-effectiveness perspective. 
They also provide policy makers with important information about issues regarding 
costs and effect to be consideredwhen including HPV testing in current follow-up 
strategies. 
Future evaluations of alternative screening strategies require assessment of costs and 
QALYs from a lifelong perspective. Since the time frame to develop cervical cancer is 
long, there is uncertainty related to rate of HPV infection persistence, development of 
future CIN, and the rate of progression and regression of present CIN, which should 
also be considered.  
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General considerations 
WHO recommends that cervical screening begin at age 25 -30 years, and stop at age 65 
years, provided that previous smears have been normal (2006 ). Given the situation in 
Sweden today, with a first peak in incidence of cervical cancer in the age group 25-49 
years (Figure 6.1 a and b), postponing screening start until age 25 or later seems risky. 
Taking into account the natural course of the disease, screening start must precede this 
first peak.  
Figure 6.1 a  and b. Age-specific incidence of cervical cancer (number of women per 100 000 (a) and the 
age-specific portion of the total number of cervical cancer cases in percent (n=427) (b) in Sweden, 2009. 
Adapted from (Socialstyrelsen, 2010).
The second major incidence peak, women aged 60-85 years, clearly shows that older 
women comprise a risk group with poor protection against cervical cancer. Extending 
the screening program until at least age 65 years as recommended by WHO and 
complementing or replacing cytology screening with HPV testing in older women may 
be a viable pathway. An interesting and potentially highly cost-effective alternative is 
HPV-self-testing for older women. Swedish studies on such possible solutions are 
underway. 
High inclusion rates by organized population-based screening programs are crucial for 
screening efficacy. For various reasons, about 25% of all Swedish women do not 
participate in screening. Introduction of self-HPV testing may be an additional 
screening modality to help improve screening coverage. 
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In summary, given the lessons learned from the studies included in this thesis and 
literature in the field, I believe screening could be improved by the following strategy: 
While using the same screening age reference range as today (23-60 years), women up 
to 30 or 35 years should be screened with cytology using reflex HPV testing/ HPV 
triage for ASCUS. For women over 30 or 35 years, primary HPV screening with 
cytology triage should be used, or alternatively, a combination of primary HPV testing 
and cytology. Women screened with HPV testing and cytology should be referred 
directly for colposcopy if HPV-positive and cytology-positive, using ASCUS as a cut-
off. If more pronounced cytological abnormalities are found, women should be 
directedly referred to colposcopy regardless of HPV-test result. Women who are HPV-
positive but cytology-negative should undergo repeated HPV testing after one year, and 
then be referred for colposcopy if persistently HPV-positive. Since several studies have 
shown that screening strategies based on primary HPV testing reduce the rate of CIN3+ 
in the following screening round, longer screening intervals are probably suitable.  
Considering the effects of mass HPV-vaccination, and future changes in the spectrum 
of HPV types in the population, an age limit for primary HPV testing may become 
unnecessary. Using additional biomarkers, such as TERC, viral oncogene E6/E7 
mRNA from the most important HR-HPV types, as well as p16 and L1, may improve 
specificity of screening in the likely scenario that the most carcinogenic HPV types will 
become proportionally less common. Future changes arising from the protective effects 
of prophylactic HPV vaccination will require monitoring of the cervical screening 
program to ensure that balance is achieved between the protective effects against 
cervical cancer and potential side effects.  
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